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I would like to consecrate this work to my family, particularly exhausted by these hard times. 
 
Time often changes and upsets the ancient equilibrium, 
and thus creates a vacuum demanding to fill in,  
or an overall feeling of fear against things we risk to lose again. 
The new challenges to face, instead, are nothing other than signs of the life that’s going on.
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ABSTRACT 
 
GnRH decapeptide and its receptor are two key-player of the 
neuroendocrine control of reproduction. Mutations in genes encoding 
these proteins (GNRH1 and GNRHR) are associated with Congenital 
Hypogonadotropic Hypogonadism (CHH). 
The aim of our work was to screen 450 individuals with CHH for 
mutations in GNRH1 and GNRHR genes and to determine their 
deleterious character. Two novel p.W26X and p.R31C mutations in 
GNRH1 and two novel p.T269M and p.Y290F mutations in GNRHR 
have been identified in eight CHH individuals from five different 
families. Molecular and functional characterizations have been 
performed.  
The mutation p.W26X totally disrupts GnRH structure. The 
occurrence of this variant in two sisters affected by Kallmann 
Syndrome is not explained by genetics, and offers novel insights to 
define the pathogenesis in these patients. 
The mutation p.R31C introduces a cysteine in position 8 within 
GnRH. This substitution dramatically alters protein structure and 
GnRH-dependent signaling, as assessed by impairment of binding, 
intracellular pathways as MAPK signaling or calcium mobilization, 
gene expression and biological activity. Moreover, the mutant pre-
pro-GnRH is less expressed in various cell lines compared to wild 
type. Despite the deleterious effects on protein function of p.R31C 
product, the mode of inheritance suggests a negative dominance 
with intriguing yet elusive mechanisms. 
The mutation p.T269M in GNRHR completely abolishes the binding, 
and produces a complete impairment of GnRH-dependent signals, as 
evaluated by calcium and MAPK. The homozygous status fully 
explains disease in two sisters with CHH. 
The p.Y290F mutated GnRH receptor is less able to activate the 
main intracellular GnRH-dependent cascades. The girl with CHH 
harbors a homozygous mutation from consanguineous parents, 
consistent with disease. 
In conclusion, novel GNRH1 and GNRHR mutations with deleterious 
properties are reported with their molecular characterization. In two 
cases, the disease cannot be fully explained by genetic 
abnormalities, thus opening interesting opportunities for further 
investigations in this field.  
Finally, a section on sensorineural characterization of CHH patients 
is provided. To this aim, a novel and innovative diagnostic test 
(Flavor Identification Test) has been developed as part of my Ph.D. 
thesis. This test has received a National Patent. 
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INTRODUCTION 
 
Gonadotrope axis physiology 
Reproductive function and sexual steroids 
production are coordinated by the gonadotrope axis, 
composed by the hypothalamus, the pituitary and the gonads 
(Fig. 1). The GnRH neurons, substantially settled in little 
number in the preoptic area and in the arcuate nucleus within 
hypothalamus, secrete the decapeptide in a pulsatile manner 
in response to a complex series of endogenous and exogenous 
stimuli. The frequence and the amplitude of GnRH pulses 
determine the response of gonadotrope cells within the 
pituitary, which express the GnRH receptor, a G-protein-
coupled receptor (GPCR) encoded by the GNRHR gene. 
GnRH
LH,'FSH
Stéroïdes'sexuels
Gamétogénèse
!
Gametogenesis+
Sex+steroid+production+
! !
Figure 1- Schematics of gonadotrope axis. GnRH is secreted in the median 
eminence by axons projecting from preoptic area and arcuate nucleus within 
hypothalamus. Gonadotrope pituitary cells respond by secreting the gonadotropins LH 
and FSH that ultimately drive gonadal response in terms of gametogenesis and sex 
steroids production (adapted from Beckwoldt et al. 1991). 
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A peculiar and delicate vascular system 
passing through hypothalamic arteries constitutes the 
hypothalamo-pituitary portal system, which allows 
gonadotrope cells to respond to very low ligand 
concentrations. GnRH-GnRH-R couple triggers an intracellular 
cascade that ultimately leads to biosynthesis and secretion of 
the gonadotropins LH and FSH (Fig. 2). These glycoproteins 
are secreted in the peripheral circulation and stimulate 
gametogenesis and the hormonal production in target tissues. 
 
 
The GnRH – GnRH-R couple 
The GnRH (progonadoliberin-1, UniProtKB 
P01148) is a peptidic neuro-hormone constituted by 10 amino 
acids. It is the result of a proteolytic maturation from a 92 
amino acids precursor by the pro-hormone convertase-1 that 
recognizes the GKR amino acidic sequence for cleavage 
activity (Cheng & Leung, 2005). The decapeptide, encoded by 
the GNRH1 gene (ENSG00000147437.8, OMIM 152760) 
located at 8p11.2, is totally conserved in mammals (Fig. 3).  
IP3 
Ca++ 
PLCβ 
Gq/11%
 
!
LH#beta#
FSH#beta#
Alpha#subunit#
GNRHR#
LH%
FSH%
SRE!
Gonadotrope%cell%
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Other!!
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Src! JNK!
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Figure 2 – Schematic of GnRH-dependent signaling.
The gonadotrope cell is exposed to pulsatile stimulation by the GnRH-I. The activation of GnRH receptor 
signals through different intrcellular effectors, among which mainly by Gq/11 that consequently activates 
phospholipase C and inositol phosphate / diacyl-glycerole / intracellular calcium mobilization. The activation 
of the MAPK ERK1/2 seems to pass through Src brokering, or through the activation of Ras by other 
pathways / co-ligands. These pathways concomitantly lead to increase gonadotropin subunit transcription, 
and to ultimately induce LH and FSH glycoprotein maturation and secretion.
PLC: phospholipase C; IP3 inositol tri-phosphate; CAM/CAMK: calcium-calmodulin / kinase; PKC: protein 
kinase C. For other acronyms, please refer to the section “list of abbreviations” within the manuscript. !
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Figure 3 – pedigrees of CHH families with GNRH1 mutations and interspecies alignment.
p.W26X and p.R31C GNRH1 mutations are carried in heterozygosis by all the individuals 
belonging to family 1 and 2. Sisters from family 1 are affected by Kallmann Syndrome. Filiation 
in family 2 is confirmed by DNA micro-satellites. All the nucleotide base changes affect highly 
conserved residues. The interspecies alignment was powered by the UniProt consortium 
(www.uniprot.org). Clinical and demographic data of all patients are reported in Table 1. !
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Figure 4 – Pedigrees of CHH families with GNRHR mutations and interspecies alignment.
All affected patients from family 4 and 5 harbor homozygous GNRHR mutations. Parental 
genetical analysis was only available for the mother of the family 4 (subject I,2). The nucleotide 
base changes affect highly conserved residues. The interspecies alignment was powered by 
the UniProt consortium (www.uniprot.org). Clinical and demographic data of all patients are 
reported in Table 1. 
 
 
Upstream to the coding sequence, two 
regions have classically been identified as regulatory regions: 
a proximal promoter, acting between -548 and -169 base pairs 
before the transcription start site, and a distal promoter 
between -1048 and -723 that is believed to act outside the 
central nervous system (Eraly et al., 1998; Nelson et al., 
1998). 
 
The GnRH receptor (GnRH-R, UniProtKB 
P309683) is encoded by GNRHR (ENSG000001091637, OMIM 
1388505) located at 4q13.2. The product is a characteristic 
tail-less GPCR, coupled to a Gq/11 protein. The absence of a 
carboxyl-terminal tail in mammalian GnRH receptors is 
correlated with a lack of rapid desensitization and seems to be 
crucial for the physiologic response to pulsatile exposition to 
GnRH-I (Davidson et al., 1994; McArdle et al., 2002a; b). 
GnRH-R is believed to be expressed at a very low rate on 
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plasma membranes of gonadotrope pituitary cells (Finch et al., 
2009), and is probably gathered mainly in membrane rafts, 
where it is coupled to different downstream effectors.  
 
The main components of GnRH signaling 
cascade are represented by Gq/11 protein, C-beta 
phospholipase, diacyl-glicerol and tri-phosphate inositol, 
intracellular calcium mobilization and MAP kinase cascade (Fig. 
2). All of these mediators, together with a series of calcium-
dependent kinases and transcription factors, are needed to 
activate LH-beta, FSH-beta and alpha-subunit promoters and 
to inhibit GNRHR transcription. 
The frequence and the amplitude of GnRH pulses seem to 
influence and orientate the transcription of specific gene 
products. Indeed, low amplitude / low frequence pulses mainly 
stimulate FSH-beta transcription. Conversely, high-frequence / 
high-amplitude pulses mainly drive LH-beta transcription 
(George & Seminara, 2012). The coordinated and dynamic 
sequence of GnRH stimulation is at the basis of the ovulatory 
LH surge in women and female mammals and on the other 
hand is needed to determine the early FSH increase in 
follicular stage (Gianetti & Seminara, 2008).  
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Congenital Hypogonadotropic Hypogonadism (CHH) 
The CHH represents a well-recognized cause 
of pubertal failure in men and women (Young, 2012). In the 
vast majority of patients, the main cause derives from a 
concomitant deficiency in LH and FSH secretion. This may be 
reflected by a hypothalamic defect or by a pituitary resistance. 
Both causes ultimately drive LH and FSH insufficiency, 
impeding a normal gonadal endocrine and exocrine function. 
CHH patients, indeed, constantly have sex steroids or gonadal 
peptides deficiency (Giton et al., 2015; Trabado et al., 2014; 
Trabado et al., 2011). This impairment is already overt during 
the early physiologic stages of embryonic gonadotrope 
activation in mankind (Bouvattier et al., 2012). The prevalence 
of CHH is around 1:4,000 – 1:10,000 in men, and is believed 
to be 2-5 fold less frequent in women. 
It is about 20 years that the CHH has been extensively studied 
and classed according to patho-physiological and genetic 
bases. A global distinction in CHH has to be made between the 
forms with an ontogenetic abnormality, and those with a 
deficiency in gonadotrope signaling. 
The former CHH is a developmental disease concerning the 
region comprising and beyond the olfactory placode, from 
which olfactory nerves as well as GnRH neurons originate and 
differentiate. The paradigm of this anomaly is Kallmann 
Syndrome (KS) that is clinically mirrored by the presence of 
CHH and olfactory impairment (anosmia or hyposmia). 
The latter form is resumed solely by the gonadotropin and sex 
steroids deficiency, without any sign of sensorineural 
involvement, and is here and thereafter reported as 
normosmic isolated hypogonadotropic hypogonadism (nIHH). 
The nIHH seems to be related to an isolated abnormality of 
neuroendocrine signaling concerning a hypothalamic (GnRH) 
or a pituitary (GnRH-R or gonadotropins) defect, without overt 
anatomic or ontogenetic defects. Latest advances 
demonstrated a delicate neuronal circuitry controlling the 
correct GnRH homeostasis, passing through kisspeptinergic 
(Kiss neurons) or neurokininergic (KNDy neurons) systems. 
These systems represent the pubertal clock in humans and are 
variably influenced by several endocrine signals, 
neurotrasmitters and physical cues, integrated in a complex 
anatomical neuroendocrine system (Pinilla et al., 2012). 
 
! 17!
Genetics of CHH 
Several genes have been associated with 
CHH. A recently updated list of genes involved in CHH forms 
and in syndromic associations is reported in Table 1. The list of 
candidate genes is still expanding, as genetics now explains 
about 50% of cases. The enrichment of genetic abnormalities 
in CHH might suggest that more genes will be identified in the 
future. The products of genes involved in KS are mainly 
constituted by proteins involved in axon growth and output, in 
neuron routing and migration, and in mechanisms of cellular 
attraction or repulsion. These proteins may often interact by 
constituting a complex framework. Anosmin, the product of 
KAL1 gene, is a complex secreted protein able to facilitate 
neuron migration. Disruption of KAL1, located on X-
chromosome, as documented in large deletions or point 
mutations, lead to the severe X-linked form of KS (Franco et 
al., 1991; Legouis et al., 1991). 
FGFR1 is a tyrosin-kinase receptor largely expressed in 
developing brain that might interact with anosmin. Loss-of-
function mutations in FGFR1 are associated with nIHH, KS and 
specifically those with midline defects, as labio-palato-schisis 
and dental agenesis (Dode et al., 2003). FGF8 and FGF17 
specifically bind FGFR1 and seem to be responsible of FGFR1-
like CHH forms (Falardeau et al., 2008). Interactome and 
networking analyses have allowed the identification of other 
actors interplaying the FGFs pathways, and have recently been 
found mutated in CHH patients (Miraoui et al., 2013). 
Prokineticin-2 is a secretory protein involved in several 
physiologic processes, among which neurogenesis. Alterations 
of this protein, as well as of its cognate receptor prokineticin 
receptor-2 are associated with KS, nIHH and with multiple 
pituitary hormone deficiency. These are the only genetic 
abnormalities in CHH arisen from knocked-out animal models, 
and not initially from patients (Dode et al., 2006; Matsumoto 
et al., 2006). 
Semaphorin 3A is one of the latest molecules implicated in KS. 
A large deletion involving SEMA3A was associated to a 
dominant form of familial KS (Young et al., 2012). Other 
proteins belonging to semaphorin family actually represent 
good candidates for mutational screening in CHH.  
All these reports strongly support the hypothesis that 
disruption of the complex molecular cues involved in neuronal 
! 18!
migration are fundamental for the understanding of KS 
pathogenesis. 
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Genes encoding the actors directly involved 
in GnRH signaling, like the GnRH ligand (GNRH1) and receptor 
(GNRHR) are obvious candidates for nIHH, without impairment 
in GnRH migration (see after). Genes encoding other 
important components of the neuroendocrine network have 
been demonstrated to be altered in nIHH. Indeed the 
identification of kisspeptin or KNDy neurons offered the 
opportunity to identify other genes associated to nIHH. 
Mutations involving the kisspeptin ligand (KISS1) have only 
recently been described (Topaloglu et al., 2012), whereas the 
alterations in kisspeptin receptor (KISS1R or GPR54) were 
already known (de Roux et al., 2003). Neurokinin B (NKB or 
TAC3) and its cognate receptor (NKBR or TAC3R) are two main 
causes of nIHH (Topaloglu et al., 2009). Isolated disruption of 
genes encoding gonadotropins also produces nIHH (Weiss et 
al., 1992). These reports and the clinical pictures associated 
support the evidence that nIHH may be considered the result 
of GnRH networking disruption, without any ontogenetic 
alteration. 
 
Other genes encoding proteins with wider 
tissue distribution or transcription factors involved in several 
and shared metabolic intracellular cascades are responsible for 
syndromic forms that contain CHH. From a clinical point of 
view, it is important to correctly identify these forms in order 
to set up the correct clinical approach, and to search for 
treatable associated conditions. Different syndromes including 
CHH are reported in Table 1. 
 
The identification of various genes has led 
scientists to define a pattern of genetic inquiring from a 
correct “phenotypization” of patients after the first clinical 
approach, in order to orientate genetic screening (Costa-
Barbosa et al., 2013). After exclusion of olfactory disorders, a 
series of other associated features (like renal or dental 
agenesis, midline defects, bimanual synkinesis) has to be 
specifically searched to improve diagnostic power and more 
appropriately favor genetic counseling. By contrast, it is of 
note that mutations within the same genes may be associated 
to different forms and severity of disease. Furthermore, even 
the same mutations may be accompanied by more or less 
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severe clinical pictures, indicating a remarkable variable 
expressivity. Pitteloud et al. first described a family carrying 
the same FGFR1 mutation in which some individuals presented 
KS, some other anosmia, nIHH or only a delayed puberty 
(Pitteloud et al., 2007). As the list of candidate genes 
lengthens, more cases of oligogenism (i.e. the concurrence of 
different gene mutations in CHH individuals) have been 
described. The presence of additional genes in the same 
individuals may contribute to explain the diversity of disease in 
probands. One may hypothesize that the participation of 
various genes creates the backbone and the «fragility» of 
gonadotrope axis, more or less unveiled by associated factors 
or stimuli, as was already reported in women with 
hypothalamic amenorrhea (Caronia et al., 2011).  
 
Involvement of GNRH1 and GNRHR in CHH 
Despite the obviousness of GnRH receptor 
implication in CHH, genetic research for GNRHR locus has been 
dampened. Indeed, the previous hypothesis was that, since 
the administration of GnRH was able to increase FSH and LH in 
patients with nIHH, a mutation could have unlikely occurred in 
GNRHR. By contrast, numerous cases of nIHH associated with 
GNRHR mutations have been reported since 1997 (de Roux et 
al., 1997; Kim et al., 2010). 
Unlike the GnRH receptor, a natural murine model lacking the 
peptide GnRH was already described in 1977 (Cattanach et al., 
1977). These animals had an isolated hypogonadotropic 
hypogonadism. In parallel, the gene encoding the GnRH 
precursor was identified and characterized by Seeburg and 
colleagues (Adelman et al., 1986). Thereafter, Mason 
identified a large deletion in this mouse, by establishing a 
relationship between the GnRH and the hypogonadal mouse 
(Mason et al., 1986). The transgenic introduction of a 13.5 kb 
fragment containing the GNRH1 locus rescued the phenotype 
and restored fertility in these animals. Despite considerable 
effort, the involvement of GNRH1 has been difficult to 
demonstrate until 2009, when an autosomal recessive form of 
nIHH was described (Bouligand et al., 2009). The alteration 
induced a homozygous insertion of an adenine (c.18-19insA) 
with consequent frame shift and truncation at the level of the 
signal peptide. Since then only another report has described 
GNRH1 mutations associated with nIHH (Chan et al., 2009). 
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Basic studies and clinical in vivo models have contributed to 
unravel the mechanisms of ligand-receptor coupling and 
downstream signaling, and the implication of molecular 
alterations involving these factors in producing human 
diseases. 
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AIMS OF THE STUDY 
 
Aim of this work was to screen for mutations of GNRH1 and 
GNRHR loci in a large series of CHH patients and to find and 
functionally characterize novel variants.  
After a comprehensive clinical evaluation and molecular 
characterization, a functional study of novel mutants has been 
performed in order to define the deleterious effect of the 
mutant proteins and to try to understand the mechanisms of 
disease in the affected patients. 
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PATIENTS, MATERIALS AND METHODS 
 
Patients 
450 patients with CHH were enrolled in this study. Most 
patients were recruited from the French Cohort of CHH 
(Bicetre University Hospital, France). 201 patients out of 449 
were affected by KS, whereas 250 suffered from nIHH.  
Criteria for KS were:  
1) congenital hypogonadotropic hypogonadism, defined by 
clinical signs or symptoms of hypogonadism and: in men, 
serum testosterone levels below 1 ng/mL in the presence of 
low or normal gonadotropins; in women, primary amenorrhea 
and estradiol levels below 20 pg/ml in the presence of low or 
normal gonadotropins;  
2) complete anosmia, as assessed by a previous olfactory test, 
or defined by self-report;  
3) otherwise normal biochemical tests of anterior pituitary 
function and ferritin concentrations. nIHH was defined by the 
same criteria as KS except for olfactory impairment.  
In all patients, MRI of pituitary region was performed. In two 
patients serial blood samplings were drawn in order to assess 
biochemical and hormonal evolution overtime. 
The genetic study was approved by the local Hospital ethics 
committee and complied with human research guidelines as 
stated in the Declaration of Helsinki. All the patients gave their 
written informed consent before genetic analysis and hormone 
studies. 
 
Genetic analyses 
  
DNA extraction. Genomic DNA was isolated from white blood 
cells by a commercial kit (FlexiGene® DNA kit, Qiagen, The 
Netherlands). Briefly, leukocytes nuclei were obtained by 
centrifugation. Proteins contamination was minimized by a 
denaturating buffer containing a chaotropic salt and a specific 
protease. DNA was precipitated in isopropanol, recovered by 
centrifugation and washed in ethanol. After a proper dryness, 
DNA was finally resuspended in a proper Tris-HCl pH 8.5 
buffer. 
 
RNA extraction. RNA was extracted from PMNC with the 
Trizol® reagent method (Life Technologies, Carlsbad, CA, 
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USA). Briefly, whole blood was incubated in EL Buffer (Qiagen, 
The Netherlands). 6-well plates of cell cultures were washed 
once in phosphate-buffer saline (PBS) 1x. RNA was extracted 
by phenol-chloroform method with Trizol® reagent. RNA was 
finally precipitated in isopropanol, recovered by centrifugation, 
washed in ethanol and resuspended in RNAse-free water. A 
spectrophotometer (Nanodrop 1000, Thermo Scienfici, 
Waltham, MA, USA) was used to measure DNA and RNA 
concentrations. 
 
Sequencing. Direct genomic sequencing of coding exons and 
intron-exon junctions of GNRH1, GNRHR were performed. PCR 
primers were designed by Primer Blast 
(http://www.ncbi.nlm.nih.gov/tools/primer-blast/). PCR and 
sequencing products were purified on a Biomek NXP-96 
Laboratory Automation Workstation (Beckman Coulter, 
Villepinte, France) with Agencourt Ampure XP and Agencourt 
Cleanseq (Beckman Coulter Genomics, Danvers, MA). 
Sequencing products were analyzed with an automated 
capillary sequencer (ABI PRISM 3130xl Genetic Analyzer; 
Applied Biosystems, Foster City, CA). Electropherogram-
derived sequences were compared with NCBI references using 
SeqScape Software 2.6 (Applied Biosystems, Foster City, CA). 
Microsatellites genotyping was performed to confirm filiation 
(Powerplex 16 System®, Promega, Madison, WI). For GNRH1, 
apart from coding exons and intron-exon junctions, the up-
stream and down-stream promoter encompassing 1100 bp 
before the transcription start site, and the entire intron 1, 
whose sequence is usually retained in extra-hypothalamic 
tissues, were also sequenced. 
 
DNA constructs design and site-directed mutagenesis 
The pCMV6 vector containing the wild-type (Tello et al., 2012) 
GNRH1 cDNA was obtained by Origene Technologies, Inc. 
(Rockville, MD, USA, ref no. RG212991) with a modification by 
a carboxyl-terminal GFP tag. The mutation c.91C>T (p.R31C) 
has been reproduced with site-directed mutagenesis by 
QuikChange Stratagene II (Agilent Technologies, CA, USA) 
according to manufacturer’s instructions.  
Phosphorylated-5’ sense and antisense primers sequences 
were as follows: 5’-GCACTGGTCCTATGGACTGTCGCCCTG-
GAGGAAAGAGAGAT-3’; Antisense: 5’ATCTCTCTTTCCTCCAGG-
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GCGACAGTCCATAGGACCAGTGC-3’. WT and mutated 
sequences have been validated by restriction enzymes and 
Sangers sequencing thereafter. 
The two GNRHR missense mutations were prepared using 
QuikChange Stratagene II from a WT GNRHR pcDNA3.1+ 
vector (Missouri S&T cDNA Resource Center). Phosphorylated-
5’ sense and antisense primers sequences were as follows: 
(p.T269M; c.806C>T) Sense: 5'-
GCACGGCTGAAGACTCTAAAAATGATGGTTGCATTTGCC-3'; 
Antisense: 5’-
GGCAAATGCAACCATCATTTTTAGAGTCTTCAGCCGTGC-3’; 
(Y290F; c.869A>T) Sense: 5’-
CTACTATGTCCTAGGAATTTGGTTTTGGTTTGATCCTGAAATGTTAA
-3’; Antisense: 5’-
TTAACATTTCAGGATCAAACCAAAACCAAATTCCTAGGACATAGTA
G-3’. Expression construct sequences were confirmed with 
Sanger sequencing. The WT human GNRHR and the two 
mutants T269M and Y290F were finally modified by CDS 
cloning into a pCMV-Flag to encode an amino-terminal Flag by 
a PCR approach. We chose the EcoRI and BglII sites, that are 
sequentially located in the multilinker region of the receiving 
pCMV. The artificial construct was obtained by a PCR 
amplification of the original pcDNA3.1+ GNRHR with a former 
primer 5’ to 3’ containing: 1) four random nucleotides; 2) a 
site for the restriction enzyme EcoRI; 3) one base in excess for 
keeping the “in frame” codonic sequence; 4) 20 nucleotides of 
the CDS opening deprived of the ATG encoding the starting 
methionine. The reverse primer was constructed in a similar 
manner as above, and contained from 5’ to 3’: 1) four random 
nucleotides; 2) the site for the restriction enzyme BglII; 3) 20 
nucleotides of the CDS closing sequence containing the 
reverse complement of the stop codon. The customization was 
therefore: sense 5’-ATTAGAATTCAGCAAACAGTGCCTCTCCTGA-
3’; antisense 5’-GCCGAGATCTTCACAGAGAAAAATATCCAT-3’. 
The product of amplification was then cloned into a pCMV-
Flag-Ampi resistant vector pre-digested by EcoRI and BglII by 
T4 ligase according to ligation procedure. The product of 
ligation has been finally used for competent XL-Gold 
transformation and plated in 10 cm-dished containing LB-Agar 
+ ampicillin. Colonies were picked up, cultured in LB-ampicillin 
and harvested for DNA plasmidic extraction by MIDI-prep 
commercial kit (Macherey-Nagel, Dueren, Germany). The 
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correct positioning of the insert was confirmed by digestion 
with EcoRI/BglII and by Sangers sequencing. All reactions 
were performed according manufacturers’ instructions. 
 
In silico analyses 
Inter-species conservation and sequence alignment was 
performed by means of Homologene on NCBI databases 
(http://www.ncbi.nlm.nih.gov/homologene). Single nucleotide 
polymorphisms were detected through NCBI platform (the 
same as above, /SNP). Primer design was performed using 
Primer Blast with optimal 60°C-Tm calculations by Schildkraut 
et Lifson 1967 et Breslauer 1989. Primer sequences where 
checked by OligoAnalyzerTM software.  
Prediction of peptide cleavage was performed by means of 
Prop v.1.0b ProPeptide Cleavage Site 
(http://www.cbs.dtu.dk/services/ProP/). Prediction of protein 
function after selective amino acid substitution was obtained 
by means of Alamut® (Interactive Biosoftware, Rouen, 
France), AlignGVD (http://agvgd.iarc.fr/agvgd_input.php/), 
Polyphen-2 (http://genetics.bwh.harvard.edu/pph2/), SIFT 
(http://sift.jcvi.org/) and PANTHER Coding SNP Analysis tool 
(http://www.pantherdb.org/tools/csnpScoreForm.jsp). 
 
Peptide custom and stability 
“Wild type” (pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2) 
and “R31C” (pGlu-His-Trp-Ser-Tyr-Gly-Leu-Cys-Pro-Gly-NH2) 
mutant GnRH were synthesized by a custom peptide 
manufacturer (Eurogentec®, Liège, Belgium). Molecular 
weight was confirmed by MALDI-TOF and purity was assessed 
at ~95% by the manufacturer. 
Lyophilized products were suspended in sterile water in order 
to obtain 0.1 mM aliquots and conserved frozen at -150°C. 
LC-MS/MS was performed with Quattro-LCZ triple quadrupole 
mass spectrometer equipped with the orthogonal electrospray 
source (Micromass, Manchester, UK) to analyze peptides 
stability in solution. Peptides solutions (water and cell culture 
medium) were incubated 24-h at room temperature for these 
stability studies. 
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Cell lines 
Several cell lines were used for the experiments.  
 
HEK293T (Human Embryonic Kidney 293 cells, ATCC CRL-
11268) cells were used for experiments in GnRH-I peptide 
signaling, as luciferase assays and Western Blot. For this 
purpose, cells were transiently transfected with pcDNA3.1+ 
vector of human GNRHR (Missouri S&T cDNA Resource Center, 
Rolla, MO), as they do not express GnRH-R endogenously. 
They were also used for the studies of pre-pro-hormone 
GnRH-I (fluorescence studies, MTT assays, western blots) WT 
and R31C mutant (see after), using GNRH1-GFP tagged 
pCMV6 (Origene Technologies, Inc., Rockville, MD, USA). 
Finally, HEK293T cells were used for functional studies of 
mutant GnRH-Rs (luciferase assay, western blots), after 
transient transfection of WT or mutant receptors in pcDNA3.1+ 
or pCMV6-Flag vectors (see after). 
 
COS-7 (CV-1 –simian- in Origin, carrying the SV40 genetic 
material, ATCC CRL-1651) also do not express GnRH-R. They 
were used in competition radioligand binding assays in the 
functional analyses of GnRH-I peptides and of mutant GnRH 
receptors. They were also used in inositol phosphate (Mason et 
al., 1986) accumulation in the same studies. 
 
Murine gonadotrope LbetaT2 cell line was kindly provided by 
Dr. Mellon laboratory (Turgeon et al., 1996). These cells 
endogenously express GnRH-R and are able to express 
gonadotropin subunit transcripts and to secrete mature LH 
glycoprotein after GnRH treatment. These cells were used for 
studying mutant GnRH-I peptides by gene expression analyses 
and by LH assay in supernatants. They were also used for 
intracellular calcium assays by Fura-2 and for WB. 
 
Att-20 cells (ATCC CRL-11285) are murine corticotrope cells 
expressing type-1 pro-hormone convertase and are able to 
cleave pre-pro-hormones containing a GKR sequence (such as 
pro-opio-melanocortin or pre-pro-GnRH). These cells were 
used for the studies on pre-pro-GnRH-I, by fluorescence 
microscopy, WB and MTT assay. 
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Gn-11 cells originate from a murine embryonic neuroblastoma 
endogenously expressing GnRH at low rate. They were kindly 
provided by Radovick group (Zhen et al., 1997). Gn-11 were 
used for the studies on pre-pro-GnRH-I, by fluorescence 
microscopy, WB and MTT assay. 
 
A375 melanoma (ATCC CRL-1619) cell line was used for 
studies on pre-pro-GnRHIs. Cells were transiently transfected 
with graded doses of WT or mutant GNRH1-GFP. The number 
of GFP-positive cells was computed on a fluorescence 
microscopy (see after). 
 
H727 neuroendocrine tumor (ATCC CRL-5815) cell line was 
used as above, especially for studies on pre-pro-GnRH-Is by 
fluorescence microscopy. 
  
All cell lines were cultured in different cell media in accordance 
with their specific requirements. The choice of plates and wells 
was undertaken according to the specific assay and procedure 
to be performed. All transfection studies were performed by 
means of Lipofectamin 3000™ reagent (Invitrogen, Cergy 
Pontoise, France) according to manufacturer’s instructions. 
 
Competition radioligand binding assays 
The high affinity GnRH analog, [His5,D-Tyr6]-GnRH was radio-
iodinated as previously described (Flanagan et al., 1998) and 
purified using Sephadex chromatography. COS-7 cells were 
transiently transfected with human GnRH-R DNA construct 
containing the human WT GnRH-R or the T269M and Y290F 
GNRHR mutants using 6 µg of DNA and 30 µl FuGene HD 
(Promega Corporation, Madison, WI) per 10 cm dish and 
seeded into 12-well plates. Two days after transfection cells 
were washed with HEPES-DMEM containing 0.1 % bovine 
serum albumin (2 x 1ml, HEPES-DMEM-BSA) and incubated 
with 125I-[His5,D-Tyr6]-GnRH (100,000 CPM per well). For 
the study of mutant R31C cys-8 GnRH-I peptide, various 
concentrations of WT GnRH or R31C GnRH (4 h, 4°C) were 
used in a total volume of 0.5 ml. For the study of mutant 
GnRH receptors, various concentrations of sole WT GnRH were 
administered for 4h at 4°C in a total volume of 0.5 ml. In both 
studies, cells were washed with phosphate-buffered saline (2 x 
1ml) and lysed with NaOH (1 ml, 0.1 M). Cell-bound 
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radioactivity was counted in a gamma counter and IC-50 
values were calculated using GraphPad Prism (GraphPad 
Software Inc, San Diego). 
To determine whether R31C GnRH binds covalently to the 
GnRH-R, transfected COS-7 cells were incubated with WT 
GnRH (10-8 M), R31C GnRH (10-5 M) or HEPES-DMEM-BSA 
alone (2 h, 4° C), washed with HEPES-DMEM-BSA (1ml) and 
incubated in HEPES-DMEM-BSA (5 ml, 1 h, 4° C) to allow 
dissociation of non-covalently bound peptide, before the 
binding assay was performed as above. 
 
Fluorescence microscopy 
Cells were seeded in 24-well plates. At about 75% confluence, 
cells were transfected by either WT GNRH1 pCMV6, R31C, 
equimolar WT+R31C concentrations, excess of mutant plasmid 
(WT:R31C 1:4), eGFP-pcDNA3.1 or empty pCMV6 vector using 
Lipofetacmin3000™ method according to manufacturer’s 
instructions. 24 h after transfection, living cells were visualized 
under the inverted microscope Olympus IX51 equipped for 
epifluorescence and phase contrast microscopy (Olympus, 
Milan, Italy). The images were captured at 40x and acquired 
with Olimpus Digital Camera F-View II (Olympus, Milan, Italy). 
As positive control we used transient transfection with eGFP-
pcDNA3.1; empty pCMV6 was always used as negative control. 
Cell count was calculated by the computer-assisted Cell^F® 
dedicated software (Olympus Europe Software Informer). The 
intensity of GFP signal was calculated as average of all visible 
cells in each microscopic field with compensation method 
between images and measured after extraction of background. 
Images were acquired at 1024x1024 pixel resolution and using 
0.3 mm Z-stacks. 
 
Measurement of intracellular free calcium concentration 
([Ca2+]i) 
LbetaT2 cells were kept in serum free medium overnight and 
then loaded with 2 µM Fura2-AM for 45 min at 37°C. The 
experiment was conducted in HEPES buffer (in mM; 116 NaCl, 
5.6 KCl, 1.2 MgCl2, 5 NaHCO3, 1 NaH2PO4, 20 HEPES ph 7.4) 
in the presence of extracellular Ca2+ (EGTA 100µM + CaCl2 
300µM). Single images of fluorescent emission at 510 nm 
under excitation at 340 and 380 nm were taken every 5 
seconds by a dedicated camera-equipped software. Changes in 
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[Ca2+]i in response to GnRHs were monitored using the Fura2 
340/380 fluorescence ratio. Basal ratio was arbitrarily 
considered as 1. Ca2+ responses over basal level were given 
either as maximal rise of [Ca2+]i or as area under the curve 
(for 2 min after agonist addition). 
 
Inositol phosphate accumulation 
COS-7 cells were transiently transfected by electroporation 
with human WT or mutant GnRH-R DNA (10 µg/15 cm dish), 
seeded into 12-well plates and radiolabeled by overnight 
incubation with myo-[3H]Inositol (0.5 µCi/well, American 
Radiolabeled Chemicals, St Louis, Mo). Radiolabeled cells were 
washed and incubated (30 min, 37° C) in IP medium (HEPES-
DMEM-BSA supplemented with 10mM LiCl), then stimulated 
(60 min, 37° C) with various concentrations of WT GnRH, or 
WT and R31C GnRH, or equal concentrations of WT GnRH and 
R31C GnRH. Incubations were stopped by removal of the 
medium and cells were lysed by addition of formic acid (1 ml, 
10 mM). IP were extracted from cell lysates using Dowex 1 
X8-200 chromatography and counted using a liquid 
scintillation counter (Packard). EC-50 and Emax values were 
calculated using GraphPad Prism (GraphPad Software Inc).  
 
Serum Responsive Element (SRE) luciferase assay 
luc2P/SRE/Hygro plasmid (Promega, Madison, WI) was used to 
test luciferase production in response to MAP kinase activation 
as a reporter gene system. HEK293T cells (1.2x 104 cells/well) 
were seeded 72 h before testing in high-glucose Dulbecco’s 
minimal essential medium (DMEM, Invitrogen, Cergy Pontoise, 
France) containing 2 mM glutamine, 100 IU/mL penicillin, 100 
mg/mL streptomycin, and 10% heat-inactivated fetal calf 
serum at 37°C in 96-well plates. Twenty-four hours before 
testing, cells were co-transfected in serum free OptiMEM, 
using Lipofectamine 3000 with the plasmids for human GnRH 
receptor, luc2P/SRE/Hygro and pMIR-REPORT™ beta-
galactosidase vector (Applied Biosystems, Foster City, CA). For 
the study of mutant GnRHs, WT GnRH, R31C, WT+R31C or 
vehicle were added at different dilutions (from 10-10 to 10-6 M). 
For the study of mutant GnRH receptors, a dose-response 
curve with serial concentrations of the sole WT GnRH was 
established. In both studies, after a 5h-incubation cells were 
harvested and assayed for luciferase activities using a 
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luminometer (Victor, Perkin Elmer, Waltham, MA, USA). To 
standardize for transfection efficiency, the relative light units 
were normalized by the galactosidase activity at optical 
density. EC-50 and Emax values were calculated using 
GraphPad Prism (GraphPad Software Inc). 
 
Western blots 
For the study on mutant GnRH-I, LbetaT2 cells were starved 
for 18h in serum-free DMEM before treatments, then exposed 
to 10-8 M of WT, 10-8 M of R31C, the combination of 10-8 M of 
each peptide or vehicle. Cells were harvested at 0, 5, 10, 15 
and 30 min after treatment.  
For the study of mutant GnRH receptors, HEK293T cells were 
transiently transfected as reported above with either WT or 
mutant T269M and Y290F GNRHR, serum-full medium or 
vehicle in OptiMem serum-free medium by Lipofectamin 3000. 
The day after cells were exposed to 10-8 M or 10-9 M WT GnRH 
and harvested after 5 or 20 minutes’ of exposition to WT 
GnRH-I. 
Western blotting analyses were performed on SDS-page as 
previously described (Maione et al., 2013a). For protein 
subcellular fractionation, membrane were extracted by 
differential centrifugation with dodecyl-beta-maltoside 
separation (Sigma Aldrich®, St. Louis, MO, USA). Briefly, cells 
were plated in 6-well plates, transfected by Flag-couples WT or 
mutant (T269 and Y290F) human GNRHR and harvested for 
protein extraction the following day. After the first 
centrifugation, pellets were lysated by sonication and 
resuspended for 1h in 50 uL of a solution containing 4 mg/mL 
dodecyl-beta-maltoside. Solutions were then centrifuged at 
4°C for 1h and supernatants were collected for subsequent 
blots. 
Rabbit anti-phospho-Akt and mouse anti phospho-MEK1/2 
(Cell Signaling Technology), mouse anti-total p44/p42 ERK1/2 
and anti-phospho-ERK1/2,  (Santa Cruz, Dallas, Texas, USA, 
no. sc-514302, and sc-136521, respectively) were used at 
various dilutions as appropriate. Murine anti-GnRH-I was used 
at 1/800 -1/1000 dilution (Santacruz), monoclonal anti alpha-
tubulin at 1/2000 (Sigma Aldrich, St. Louis, MO, USA). Mouse 
anti-Na/K-ATPase (Santacruz) was used at 1/1000 dilution as 
membrane-specific housekeeping protein. Mouse anti-beta-
actin and anti-Flag were used at 1/2500 dilution. For 
! 33!
secondary peroxidase-coupled antibody incubation, 
membranes were washed and hybridized for 90 minutes at 
room temperature (anti-mouse or anti-rabbit Fc, 1/5000 or 
1/10,000 dilution, as appropriate). 
Chemiluminescent detection was performed with ImageQuant 
LAS 4000 Mini equipment (GE Healthcare, Buckinghamshire, 
UK). After variable exposition of horse-radish peroxidase 
substrate (Immobilon®, EMD Millipore, Molsheim, France). 
Protein quantification was assessed by pixel density 
quantification with ImageQuant® software. 
 
Gene expression study  
LbetaT2 cells were grown at 106 cells/well density, in 6-well 
plates and starved in serum-free DMEM for 18h before tests. 
After 5 h of incubation with 10-8 M WT, R31C, the combination 
of 10-8 M WT + 10-8 M R31C peptides or vehicle, cells were 
washed with 1x PBS and total RNA was isolated using Trizol® 
(Invitrogen, Germany). 
Lhb (murine LH beta subunit) transcript was quantified by 
real-time RT-PCR, using an ABI Step One Sequence Detector 
(Applied Biosystem, Foster City, CA, USA) as previously 
described (Bouligand et al., 2010). 
 
MTT assay 
HEK293T, Att-20 and Gn-11 were plated in 96-well plates. 
Before testing, cells were transfected by using Lipofectamine 
3000™ method with the WT human GNRH1 receptor, mutant 
R31C, combination of WT+R31C plasmids or with empty 
vector in serum-free OptiMEM. 48h after transfection, GFP 
signaling was checked and cells were starved in high-glucose 
DMEM containing 2 mM glutamine, 100 IU/mL penicillin, 100 
mg/mL streptomycin, and 10% heat-inactivated fetal calf 
serum plus the tetrazolium MTT at 37°C for 1 h. After 
solubilization in isopropanol, the absorbance at 570 nm was 
measured by VICTOR™ X4 Multilabel Plate Reader. The 
percentage of viability was normalized upon control (non-
transfected) cells (100% viability). 
 
LH assay 
LbetaT2 cells were starved overnight in serum-free DMEM. The 
day of assay cells were exposed to 10-8 M WT, R31C, the 
combination of 10-8 M of each peptide or vehicle for 5 h. Cell 
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culture supernatants were collected and rapidly stored at -80 
°C. LH concentration was measured in cell culture media by 
using a previously described ELISA method (Garrel et al., 
2011) with reagents supplied by Dr. Parlow (National Hormone 
and Peptide Program, Harbor-UCLA Medical Center, Torrance, 
CA). The minimum detectable LH concentration was 0.2 ng/ml, 
and the interassay coefficient of variation was less than 10%. 
 
Statistical analyses 
Only nonparametric tests were used. Friedman's test was used 
to compare three or more matched groups and Kruskall-Wallis 
test for unmatched groups. These analyses were followed by 
Dunn’s post comparison test. Differences were significant 
when p < 0.05 (*p<0.05, **p<0.01, ***p<0.001). Statistical 
analyses were performed using GraphPad Prism version 5.0d 
(GraphPad Software Inc., San Diego, CA, USA). 
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RESULTS 
 
A. Genetic Analyses 
 
From the total cohort of CHH patients we 
identified 10 different variants in GNRH1 and GNRHR coding 
regions (Fig. 4).  
In GNRH1 we identified the mutations: 
- c.18-19insA, 
- c.77A>G, p.W26X, 
- c.91C>T, p.R31C.  
In GNRHR we identified:  
- c.111T>G, p.I37S,  
- c.311A>G, p.Q106R,  
- c.710G>A, p.R240Q,  
- c.806C>T, p.T269M,  
- c.846C>G, p.P282R,  
- c.869A>T, p.Y290F, 
- c.969A>G, p.Y323C. 
  
Of these mutations, the c.18-19insA in 
GNRH1, and the p.I37S, p.Q106R, p.R240Q, p.P282R and 
p.Y323C in GNRHR were already described and characterized  
(Beneduzzi et al., 2014; Bouligand et al., 2009; de Roux et al., 
1997; Kim et al., 2010; Trarbach et al., 2006). We focused 
only on mutations never described or functionally 
characterized, the p.W26X, the p.R31C in GNRH1, the 
p.T269M and the p.Y290F in GNRHR. Detailed demographic, 
clinical, biological and genetic data of individuals carrying 
these novel variants are reported in Table 2 and Figg. 3 and 4. 
The mutation c.77A>G in GNRH1 consisted in a A>G amino 
acidic substitution in position 77. Alignment with orthologs 
revealed a complete conservation of tryptophan in position 3 
of GnRH in mammals (Fig. 3).  
More importantly, the missense in position 26 of the pre-pro-
GnRH generated a stop codon in the third residue of the 
decapeptide, thus abolishing almost completely the translation 
product, the ligand sequence and structure. The mutation was 
carried in heterozygosis in both probands and the father. 
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Thr269Met 
Tyr290Phe Ile37Ser Gln106Arg 
Arg240Gln 
Pro282Arg 
Tyr323Cys 
c.18-19insA 
Arg31Cys Trp26X 
Pre$pro$GnRH$I,
GnRH,receptor$I,
A,
B,
Figure 5 – Schematic two-dimensional representation of the GnRH-I pre-pro-hormone 
and the GnRH type-I receptor.
Each amino acid is represented by a circle. In both panels, mutations found in the current 
CHH cohort are reported. Among these, variants already characterized are depicted in black, 
the novel variants are in red.
A.  Pre-pro-GnRH-I. Decapeptidic sequence is shown in grey. The GKR sequence for pro-
hormone convertase is shown in pink.
B.  The TMDs are depicted as grey box and enumerated from I to VII in Latin numbers. Small 
black circles denote already described variants associated to CHH.
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In order to exclude a contra allelic event in GNRH1 locus, the 
complete sequencing of the two regulatory regions of GNRH1 
until -1100 bp before the transcription start site was 
performed and did not reveal variants. The analysis of the 
entire sequence of the intron 1, retained in extra hypothalamic 
tissues, also did not reveal abnormalities. Finally, the GNRH1 
sequence from PMNC-cDNA (performed in the patient 1 only) 
showed the coexistence of WT and mutant form, indicating 
expression of the WT allele in this patient (Fig. 6A). No 
mutations were found in other genes involved in CHH, like 
GNRHR, FGFR1, PROK2, PROKR2 and WDR11. 
 
The mutation c.91C>T (p.R31C) in GNRH1 
produced a missense in codon 31, replacing the arginine with 
a cysteine in the decapeptide position 8 (p.R31C, or cys-8, Fig. 
5). In family 2, the boy harbored a heterozygous mutation and 
his parents are unaffected and do not carry this mutation. 
Micro-satellites revealed that the mutation is de novo. In 
family 3, the boy carried the heterozygous mutation along with 
his mother. Both carriers are affected by nIHH. Direct 
sequencing of genomic regulatory region and the intron 1 did 
Ser$$$– Tyr$$$– Gly$$$– Leu$$$– Cys – Pro$$$0 Gly$$$– Gly$$$– Pro
T
Ser$$$– Tyr$$$– Gly$$$– Leu$$$– Arg – Pro$$$0 Gly$$$– Gly$$$– Pro A
B!
Fig. 6 – GNRH1 sequencing from PMNC-derived cDNA.
RNA was extracted from PMNC of peripheral blood (see Methods). The electropherogram from patient 1 shows 
the co-existence of WT and the c.77A>G (p.W26X) variant (open arrow, panel A). The electropherogram of patient 
3 (B) shows the co-existence of WT and the c.91C>T (p.R31C) variant (open arrow, panel B).
A"
B"
Pa#ent'1'
Pa#ent'3'
!
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not reveal abnormalities. Peripheral blood GNRH1 cDNA 
sequencing revealed the presence of WT and mutant forms, 
indicating transcriptional production of normal allele (Fig. 6B) 
and excluding a contra allelic GNRH1 event. 
 
The mutation c.806C>T (p.T269M) in GNRHR 
was carried by two nIHH sisters in homozygosis. Their mother 
carried the same mutation in heterozygosis, whereas their 
father was not available for genetic tests (Fig. 4). The 
missense mutation in GNRHR substituted a methionine in place 
of the threonine in position 269, located in the first residue of 
the sixth TMD (Fig. 5). The inter species alignment revealed a 
total conservation of this residue within all mammals (Fig. 4).  
 
The mutation c.869A>T (p.Y290F) in GNRHR 
was carried in homozygosis in the girl affected by nIHH. 
Familial study was not possible, but clinical inquiry revealed 
consanguinity in her parents. Missense mutation substituted 
the tyrosine-290 with a phenylalanine in a critical residue in 
the third extracellular loop next to the sixth TMD (Fig. 5). The 
Tyr-290 residue is totally conserved among mammals (Fig. 4). 
 
 
B. Functional molecular characterization (in silico and 
in vitro experiments) 
 
The GNRH1 mutation c.77A>G (p.W26X) was 
classified as deleterious by SIFT, PolyPhen-2 and PANTHER 
prediction tools. Since the stop codon produces a completely 
truncated peptide, and the decapeptidic structure of GnRH-I is 
universally shown to be needed for receptor binding, no need 
for further functional characterization of mutant GnRH has 
been considered. A comprehensive genetic characterization of 
contra allelic GNRH1 locus and of other CHH genes has been 
assessed (see Section A - Genetic Analyses). 
 
The GNRH1 mutation c.91C>T (p.R31C) was 
classified as deleterious by SIFT, PolyPhen-2 and PANTHER. 
Prop v1.0 predicted no alterations of pro-hormone convertase 
cleavage site after R31C introduction. R31C and WT 
decapeptides were stable over 24 h at room temperature in 
water and culture medium.  
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Figure 7 – Mass spectrometry of WT and cys-8 (p.R31C) peptides.
Peptide stability on mass spectrometry-coupled electrospray (Quattro-LC). Peptides were measured in aqueous solution 
tamponed at pH7 (ammonium acetate) and starved at 37°C overnight. WT and R31C decapeptides are found at the 
expected molecular weight (1181.6 and 1128.5, respectively). Formation of smaller fragments was absent in WT and 
negligible in R31C. Formation of R31C dimers was absent. !
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Figure 8 – Binding of WT and R31C GnRH to the GnRH receptor (GnRH-R). (A) COS-7 cells were 
transiently transfected with a human GnRH-R DNA construct and incubated with a 125I-labeled GnRH agonist in 
the presence of indicated concentrations of WT GnRH or R31C GnRH. IC-50 values are WT GnRH, 2.8 x 10-9 
M and R31C GnRH, 8.50 x 107 M. Data are means and SEM of a single experiment performed twice in 
duplicate. (B) Transfected COS-7 cells were pre-incubated with buffer alone, WT GnRH (10-8 M) or R31C 
GnRH (10-5 M) and then washed to allow dissociation of ligand not covalently attached to the GnRH-R. Pre-
incubated cells were then incubated with 125I-labeled GnRH agonist in the absence or presence of saturating 
concentration of unlabeled WT GnRH (NSB). Data are the means of two experiments performed in triplicate. 
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No dimerization of the mutant decapeptide 
was found at Matrix-Assisted Laser Desorption/Ionization 
(MALDI) mass spectrometry with time-of-flight (Fig. 7). The 
cys-8 peptide had lower affinity for GnRH-R than WT GnRH 
(Fig. 8A). Dose-response curves with SRE-luciferase assay 
showed an almost 100-fold reduction of R31C agonist versus 
WT (EC-50 4 and 314 nM, respectively, fig. 9A and insert). 
Combination of WT and R31C was not able to impair luciferase 
activity when compared to WT alone (Fig. 9A). The maximal IP 
generated by both ligands was the same indicating that the 
R31C GnRH peptide was a full agonist, as was found in the 
SRE-luciferase assay (fig. 9B and insert). IP dose-response 
curve with equal concentrations of WT and R31C peptides was 
indistinguishable from WT GnRH alone (Fig. 9B). ERK1/2 
phosphorylation was maximal at 5 min. R31C GnRH showed 
similar kinetics, but the degree of phosphorylation was 
reduced (Fig. 10A). Increasing the dose of R31C GnRH from 
10-8 to 3 x 10-7 M in the presence of 10-8 M WT GnRH did not 
reduce ERK1/2 phosphorylation after 5 min of exposure (Fig. 
10B). In LbetaT2 cells calcium response by R31C was 
significantly reduced compared to WT in terms of peak and 
area under the curve (p<0.05). Calcium peak and area under 
the curve after treatment with the combination of 10-8 M GnRH 
and 10-8 M mutant peptide was indistinguishable from WT 
GnRH alone (Fig. 11). 
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Figure 9 – Dose-response curves. 
(A) SRE-coupled luciferase assay. HEK293T cells were exposed to graded concentrations of WT GnRH, R31C and equimolar 
concentrations of WT + R31C during five hours. Luciferase activity arbitrary units by luminometry (a.l.u.) is shown as ratio on 
beta-galactosidase activity by optical density used as transfection efficiency internal control. In the insert, individual values of 
EC-50 from n=8 experiences. EC-50 was established at 4 nM for WT and at 313 nM for R31C.
(B) IP accumulation. COS-7 cells administered myo-[2-3H]Inositol after transfection. After 16 hours cells were washed and 
incubated for 1 hour with graded concentrations of WT, R31C and equimolar WT+R31C GnRH. In the insert, individual values 
of EC-50 from n=3 experiences three times each in triplicate. EC-50 was established at 0.5 nM for GnRH and at 199 nM. !
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Figure 10 - ERK1/2 phosphorylation by Western blot.  
(A) HEK293T cells were starved overnight in serum-free DMEM and then 
treated with 10 nM WT, 10 nM R31C, 10 nM WT + 10 nM R31C peptides or 
vehicle for 0, 5, 10 and 30 min. Representative of four experiments. 
Density quantification is displayed on right-hand, and data are expressed 
as mean ± SD for four experiments.  
(B) LbetaT2 cells were starved overnight in serum-free DMEM and then 
treated with a constant dose of WT GnRH (10 nM) and increasing (0 – 10 – 
300 nM) doses of mutant R31C peptide after 5 min of exposition.  
Lysates were analyzed by Western Blotting using phospho-ERK1/2 
antibodies (Cell Signaling®, open arrow) and mouse monoclonal anti alpha-
tubulin (Sigma Aldrich®, St. Louis, MO, close arrow). 
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WT GnRH significantly increased lhb 
transcript levels in gonadotropes (p<0.01), whereas R31C 
GnRH did not significantly increase these levels over baseline 
(not significant, Fig. 12A). WT GnRH strongly stimulated LH 
secretion over baseline (p<0.001). R31C GnRH significantly 
stimulated LH secretion in LbetaT2 cells supernatants over 
baseline (p=0.042, Fig.12B). However R31C GnRH was unable 
to influence lhb transcription or LH secretion in LbetaT2 cells 
by WT GnRH (Fig. 12A and B). 
The hypothesis that the cysteine in position 8 
of the R31C GnRH might form disulfide bridges with cysteine 
residues in the receptor was ruled out by the pre-exposition of 
transfected cells to each of the ligands before extensive 
washing and performing a competition binding study. No 
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Figure 11 – Effect of treatments on intracellular calcium mobilisation. 
Cells were loaded with Fura 2-AM. At the time of the experiment 100µM EGTA was added 30 sec before addition 
of 300µM of CaCl2 (Ca2+) to the medium as indicated, and cells were then stimulated with 10 nM of wild type 
(WT), mutant (R31C) or equimolar combination (10 nM WT + 10 nM R31C) or vehicle for 3 min. In the upper 
panel, representative curves of single cell recording. Each experiment mean was analysed using One-way 
ANOVA followed by Tukey’s Multiple comparison test. In the lower panels, histograms show the means ± SEM (n 
= 4) of the response to ligands as calcium peak and as area under the curve (AUC). R31C-induced peak and 
AUC were significantly lower than WT. Combined treatment by WT+R31C did not induce a different calcium peak 
and AUC compared to WT alone. Representative of at least three independent experiments, *p<0.05. !
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reduction in radiolabeled GnRH binding was observed, 
probably indicating that R31C GnRH does not form covalent 
disulfide bonds with the receptor (Fig. 8B). 
 
After pulsatile administration of WT and cys-8 
peptides at 90-min frequency, WT GnRH was more powerful 
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Fig. 12 – Effects of treatments on lhb transcription and LH secretion. 
(A) LbetaT2 cells were starved overnight in serum-free DMEM and treated either 
by 10 nM WT, R31C, 10 nM WT + 10 nM R31C peptides or vehicle. After five 
hours treatment cells were lysed for RNA extraction (Trizol®). Mouse lhb levels 
were analyzed by quantitative real time RT-qPCR. Values are expressed as 
individual ratios on 18S and represented as fold induction on vehicle as means ± 
SEM, **p<0.01. This experience was conducted n=7 times in duplicates.
(B) LH concentrations from LbetaT2 cells culture media. Cells were starved 
overnight in serum-free DMEM and incubated with 10 nM WT, 10 nM R31C, 10 
nM WT + 10 nM R31C, or vehicle for 5 hours. LH levels were measured by a 
combined rat/mouse RIA. Values are expressed as individual values and as 
means ± SEM, *p<0.05, ***p<0.001. The experiment was conducted four times 
and each sample was assayed in duplicates. !
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than R31C GnRH in inducing luciferase activity coupled to SRE 
reporter gene. Combination of WT and R31C was not able to 
impair luciferase activity when compared to WT alone (Fig. 
13). 
 
Pre-pro-GnRH-GFP sequence and the c91C>T 
substitution after mutagenesis were verified by Sanger 
sequencing. Sequencing confirmed also that no CMV promoter, 
GFP or other sequences were altered. The highest transfection 
rate was achieved in HEK293T and A375 cells, whereas the 
lowest rate was found in H727, Gn-11 and Att-20 cells. 
Expression of murine pro-convertase was exclusively found in 
Att-20 cells and not in other lineages. 
Despite variable transfection rate, in all cell lines tested, the 
number of GFP-positive cells was lower after R31C than after 
WT-GNRH1 (Fig. 14). Co-transfection by WT and different 
doses of R31C did not impair GFP signal except than in Att-20 
cells, in which a slight but not significant reduction in GFP 
signal was observed after high doses of R31C (Fig. 14).  
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Figure 13 – Luciferase activity after pulsatile treatment by GnRHs
HEK293T cells were transiently transfected with GNRHR and SRE-coupled luciferase reporter gene, and 
then exposed to four pulses of 10 nM WT, 10 nM R31C and 10+10 nM WT+R31C. After 5 minutes 
exposure to each ligand, cells were washed, and a subsequent pulse was given 90 minutes after. Five 
hours after the fourth pulse, cells were harvested for luciferase assay. Luciferase activity arbitrary units 
by luminometry (a.l.u.) are shown as ratio on beta-galactosidase activity by optical density (used as 
transfection efficiency internal control). This experience was conducted three times in octaplicates. !
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Fig. 14 – Efficiency of GNRHs transfection by GFP-positive cell count.
In upper panels, GFP positive cells are depicted by 20x magnification fuorescence microscopy. 
Transfection was performed by Lipofectamine3000™
 method with either 75 ng W
T GNRH1 pCMV6 (A and E), 75 ng R31C (B and F), 75+75 ng W
T
+R31C (C and G), or 75+300 ng W
T+R31C (D and H) in HEK293T (from A to D) or Att-20 (from E to H) cells.
(I) Quantification of GFP-positive cells in Att-20 cells. *p<0.05 by Dunn’s test. Experience conducted n=6 times.
(J) Quantification of GFP-positive cells in HEK293T, A375, Gn-11 and H727 cells. *p<0.05, **p<0.01, ***p<0.001 by Dunn’s test. Experience conducted 
n=3 times.
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Fig. 14 – Efficiency of GNRH1 transfection by GFP-positive cell count. 
In upper panels, GFP positive cells are depicted by 20x magnification fuorescence 
microscopy.  
Transfection was performed by Lipofectamine3000™ method with either 75 ng WT 
GNRH1 pCMV6 (A and E), 75 ng R31C (B and F), 75+75 ng WT+R31C (C and G), or 
75+300 ng WT+R31C (D and H) in HEK293T (from A to D) or Att-20 (from E to H) 
cells. 
(I) Quantification of GFP-positive cells in Att-20 cells. *p<0.05 by Dunn’s test. 
Experience conducted n=6 times. 
(J) Quantification of GFP-positive cells in HEK293T, A375, Gn-11 and H727 cells. 
*p<0.05, **p<0.01, ***p<0.001 by Dunn’s test. Experience conducted n=3 times. 
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Apart from the number of GFP-positive cells, 
also the intensity of GFP signal was reduced in HEK293 cells 
after R31C transfection compared to WT (Fig. 15). No change 
in HEK293T, Gn-11 and Att-20 cell viability was observed 24, 
48 and 72 h after effective transfection by WT and R31C as 
assessed by MTT assay (see Fig. 16A, B and C). 
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Figure 15 – GFP intensity in HEK293T cells. 
Cells were seeded in 6-well plates and transfected by either 75 ng WT GNRH1 pCMV6, 75 ng R31C, 75+75 
ng WT+R31C, 75+300 ng WT+R31C, 375 ng R31C or 375 ng WT plasmids with Lipofectamin3000™ method. 
The day after, living cells were visualized on the Olympus Fluorescent Microscope (see Methods). Pixel 
quantification was normalized over background. The same exposition duration was used for each acquisition. 
Pixel brute quantification was drawn in all visible GFP-positive cells in the microscopic field by Cell^F 
software. Data are expressed as Box & Whiskers (10°-90° centile). **p<0.01.
 
 
 
 
 
 
The GNRHR mutation T269M was classified 
as deleterious by SIFT, PolyPhen-2 and PANTHER. Binding and 
competition studies showed a complete absence of 
radioiodinated GnRH signal in COS-7 cells after transient 
transfection with T269M construct when compared to WT 
GNRHR (Fig. 17). 
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Similarly, dose-response curve of IP accumulation was 
completely abolished after treatment with logarithmic doses of 
GnRH (Fig. 18). 
ERK1/2 phosphorylation was very low 5 min after 10-8 M GnRH 
administration in HEK293T cells transfected with the mutant 
receptor compared to those expressing WT GNRHR. No change 
in pMEK1/2 or pAKT activation was observed after 5 min of 
GnRH-I exposition (Fig. 19). Subcellular protein extraction 
revealed the presence of Flag-coupled T269M mutant in 
membrane fractions (Fig. 20). In transiently-transfected 293 
cells no increase of luciferase activity coupled to serum 
responsive elements was detected after graded doses of GnRH 
ligand exposition in T269M transfected cells, in comparison to 
WT GNRHR (Fig. 21). 
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Figure 16 – Cell viability by MTT method in cells transfected with GNRHs.
Att-20 (A), HEK293T (B) and Gn-11 (C) cell lines were transfected with 35 ng/
well wild-type (WT), mutant (R31C) GNRH1 or empty pCMV vector in a 96-well 
plate by Lipofectamin3000™. 48h after transfection, cells were exposed to MTT 
salt + serum, and finally dissolved in isopropanol. Absorbance was measured at 
570 nm by Victor (PerkinElmer, see Methods).
Data are expressed as fold changes over controls (dotted line) of median values 
(Box & Whiskers, min-max). This experiment was conducted n=4 times in 12-
plicates.
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The GNRHR mutation Y290F was predicted to 
be damaging by SIFT, PolyPhen-2 and PANTHER. Binding 
studies showed a dramatic reduction of GnRH radioiodinated 
signal in transiently-transfected COS-7 cells compared to WT 
GNRHR (Fig. 17). 
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A dose-response curve showed a weaker induction of IP 
accumulation when compared to WT GNRHR-transfected cells. 
Apart from higher EC-50, also the Emax was consistently 
lower than that induced by WT-GNRHR transfection (FIG. 18). 
GnRH-induced ERK1/2 phosphorylation was lower in Y290F-
transfected 293 cells than in those expressing WT GnRH 
receptor, with no changes in pMEK1/2 or pAKT (FIG. 19). 
Fractionated protein extraction revealed the presence of Flag-
tagged Y290F in membrane fractions, similarly to WT GNRHR 
(Fig. 20). 
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Figure 17 – Binding of GnRH-I to WT and mutant GnRH receptors 
(hGnRHR). COS-7 cells were transiently transfected with wild-type (wt), 
Y290F, T269M human GnRH-R DNA constructs or empty pcDNA3.1+ vector 
and incubated with a 125I-labeled GnRH agonist in the presence of graded 
concentrations of GnRH-I. Data are means and SEM of a single experiment 
performed twice in triplicate. !
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Figure 18 – Intracellular inositol phosphate (IP) accumulation. 
COS-7 cells were transiently transfected with Wild-type, Y290F, T269M human GnRH-R 
or empty vector (pcDNA3.1+) and washed before the addition of myo-[2-3H]Inositol. After 
16 hours cells were washed and incubated for 1 hour with graded concentrations of 
GnRH-I. This experience was conducted three times each in triplicate.  
 
A blunt response in terms of SRE-coupled 
luciferase activity was noted only at the highest GnRH doses, 
with a remarkable reduction of EC-50 (18 vs 1.9 nM, 
respectively, p<0.001) and especially of Emax (p<0.0001) 
compared to WT-transfected cells (FIG. 21). 
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Figure 19 – Signaling of different GnRHRs by Western Blot.
HEK293T cells were transfected by either wild-type human GNRHR-pcDNA3.1+, 
or same doses of mutant Y290 and T269M GNRHR, or empty vector. GnRH-I 
was administered at 10 nM for five minutes, then cells were washed and lysated 
as described in Methods’ Section. This experiment was conducted four times.
GnRH5I ( ( (5 ( (+ ( ((((+ ( ((((((+ ( ( (5 ( ((((+(
Serum ( ( (5 ( ((5 ( ((((5 ( ((((((5 ( ( (+ ( ((((5(
 
! 52!
WT# Y290F# T269M# pCMV#
ﬂag#
eGFP# veh#
An#$FLAG$
Na+/K+$$
ATP/ase$
An#$FLAG$
Beta/Ac#n$
M#
C#
Figure 20 – GnRHR-Flag by Western Blot of subcellular protein extracts
HEK293T were transiently transfected with plasmid containing human WT, Y290F, 
T269M constructs, pCMV-Flag or eGFP. Proteins from membrane (M) or cytoplasm 
(C) fractions were differentially extracted through the dodecyl-beta-maltoside and 
centrifugation method (see Methods). WT: wild type; eGFP: green-fluorescent 
protein pCMV plasmid; veh: vehicle (non transfected).  
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C. Clinical characteristics of CHH patients harboring 
GNRH1 and GNRHR mutations 
The GNRH1 mutation c.77A>G (p.W26X) was present in two 
sisters (Fig. 3) originating from France. Their mother 
originated from continental France, whereas their father was 
born in Martinique (Béké Caucasian group). Clinical inquiry of 
their parents was unremarkable. At clinical examination, there 
were no associated signs except for anosmia. The clinical 
picture, dominated by primary amenorrhea, absent puberty 
and anosmia, evoked a typical Kallmann Syndrome. MRI 
supported this diagnosis by showing the classical 
rhinencephalic abnormalities. No other associations were found 
at clinical examination. At the time of visit they were 32 and 
28 years old (patients 1 and 2, respectively) and regularly 
received estro-progestins. One of them conceived a healthy 
daughter after several cycles of GnRH pump. 
 
The R31C GNRH1 mutation was found in two 
unrelated French families with nIHH. In both cases mutation 
was in heterozygosis. 
In patient 3, nIHH was sporadic (see Results, Section A). The 
boy presented at 19 years old with a failure to progress 
throughout puberty. At physical examination he had a partial 
pubertal development with 12-mL bilateral testes volume, and 
no olfactory impairment. Hormone assays revealed 
hypogonadism in the absence of any secondary cause (see 
Table 2). In patients 4 and 5 the GNRH1 mutation segregated 
with disease. The boy had a partial form of CHH with a 10-12 
mL testis volume, low serum testosterone and low 
gonadotropins, with a P3 pubertal stage. He had no anosmia. 
His mother had primary amenorrhea and conceived after 
ovarian stimulation, although diagnosis was established only 
at 65 years of age, when hormone assays revealed 
inappropriately low gonadotropins in regard to age. 
A clinical reevaluation to assess for nIHH reversal has been 
tried in patients 3 and 4. After 2 months of HRT withdrawal, 
testosterone levels remained within the normal range. A 
longer observation period, however, put in evidence a 
progressive insufficiency of gonadotrope axis (see Table 3). 
Both patients were instructed on their condition of oscillatory 
and relapsing form of nIHH and definitely put under HRT 
thereafter. 
! 54!
T
ab
le 2
 –
 D
em
o
g
rap
h
ic, clin
ical an
d
 g
en
etic ch
aracteristics o
f C
H
H
 in
d
ivid
u
als rep
o
rted
 in
 th
is stu
d
y. 
 In
d
ex cases (p
atien
ts) 
1
 
2
 
3
 
4
 
5
 
6
 
7
 
8
 
Phenotype 
K
S
 
K
S
 
nIH
H
 
nIH
H
 
nIH
H
 
nIH
H
 
nIH
H
 
nIH
H
 
G
ender 
F 
F 
M
 
M
 
F 
F 
F 
F 
A
ge at diagnosis 
17 
13 
19 
21 
65 
17 
15 
21 
Fam
ilial 
+
 
+
 
- 
+
 
+
 
+
 
+
 
+
/- 
G
en
etic an
alyses 
 
 
 
 
 
 
 
 
G
N
R
H
1 
W
26X
/+
 
W
26X
/+
 
R
31C
/+
 
R
31C
/+
 
R
31C
/+
 
N
orm
al 
N
orm
al 
N
orm
al 
G
N
R
H
R
 
N
orm
al 
N
orm
al 
N
orm
al 
N
orm
al 
N
orm
al 
T269M
/T269M
 
T269M
/T269M
 
Y290F/Y290F 
O
ther C
H
H
-associated genes
1 
N
orm
al 
N
orm
al 
N
orm
al 
N
orm
al 
N
orm
al 
N
orm
al 
N
orm
al 
N
orm
al 
C
lin
ical ch
aracteristics 
 
 
 
 
 
 
 
 
O
lfactory status 
A
nosm
ia 
A
nosm
ia 
N
orm
osm
ia 
N
orm
osm
ia 
N
orm
osm
ia 
N
orm
osm
ia 
N
orm
osm
ia 
N
orm
osm
ia 
B
im
anual synkinesis 
- 
- 
- 
- 
- 
- 
- 
- 
M
idline defects 
- 
- 
- 
- 
- 
- 
- 
- 
H
ypoacusia 
- 
- 
- 
- 
- 
- 
- 
- 
R
enal abnorm
alities 
- 
- 
- 
- 
- 
- 
- 
- 
B
io
ch
em
ical d
ata 
 
 
 
 
 
 
 
 
LH
 (m
U
/m
L) 
0.1 
0.9 
0.7 
1.2 
4.8 
0.9 
0.5 
1.0 
FS
H
 (m
U
/m
L) 
0.8 
1 
1.2 
1.5 
3.2 
1.2 
0.9 
1.1 
LH
 peak (m
U
/m
L) 
 
 
 
 
 
 
 
 
FS
H
 peak (m
U
/m
L) 
 
 
 
 
 
 
 
 
LH
 pulsatility 
N
A
 
+
 
- 
- 
N
A
 
N
A
 
N
A
 
N
A
 
Estradiol (pg/m
L) 
7 
10 
<
2 
7 
<
2 
12 
<
10 
<
10 
Total testosterone (ng/m
L) 
 
 
0.3 
0.8 
N
A
 
0.2 
0.3 
0.3 
A
M
H
 (m
m
ol/L) 
 
 
N
A
 
1.4 
<
0.4 
N
A
 
N
A
 
N
A
 
Inhibin B
 (ng/m
L) 
 
 
N
A
 
101 
<
15 
 
 
 
Ferritin (m
cg/m
L)) 
 
 
63 
56 
103 
 
 
 
M
o
rp
h
o
lo
g
ical d
ata 
 
 
 
 
 
 
 
 
Testicular volum
e (m
L) 
 
 
12 
10 
- 
 
 
 
O
varian volum
e (m
L) 
 
 
 
 
<
10 
 
 
 
M
R
I findings 
N
orm
al 
N
orm
al 
N
orm
al 
R
athke cyst 
N
orm
al 
N
orm
al 
N
orm
al 
N
orm
al 
 Patients 
enum
erated 
in 
num
bers 
are 
described 
in 
the 
m
anuscript 
(see 
M
ethods’ 
section). 
C
H
H
 : 
C
ongenital 
H
ypogonadotropic 
H
ypogonadism
 ; K
S
 : K
allm
ann S
yndrom
e ; nIH
H
 : norm
osm
ic isolated H
ypogonadotropic H
ypogonadism
 ; M
R
I : M
agnetic R
esonance 
Im
aging ; 1 : other sequenced genes w
ere : K
A
L1, FG
FR
1, PR
O
K
2, PR
O
K
R
2, W
D
R
11, K
IS
S
1, K
IS
S
1R
, TA
C
3, TA
C
R
3. A
 detailed list of 
C
H
H
-associated genes is reported in Table 1. 
 
! 55!
Table 3 – Clinical characterization of three CHH patients harboring the R31C GNRH1 
mutation. 
 Patient 3 Patient 4 Patient 5 
Clinical data    
Sex M M F 
Cryptorchidism No No - 
Spontaneous puberty  Yes Yes Yes 
Spontaneous menarche - - No 
Delayed puberty No No No 
Signs of reversal Yes Yes Yes 
Signs of relapse Yes Yes Yes 
Spermatogenesis NA Yes - 
Induced fertility - - Yes 
Spontaneous fertility - - Yes 
Spontaneous puberty was defined by the presence of more-than 1 stage of pubertal 
development according to Tanner Stage. Reversal hypogonadism was assessed as reported in 
Raivio et al. NEJM 2004. Relapse was defined as re-occurrence of clinical and biochemical signs 
of hypogonadism. 
 
 
The c.806C>T (p.T269M) GNRHR mutation 
has been found in two sisters issued from a consanguineous 
West-African family. Both sisters had a classical form of nIHH. 
Pubertal development was blunted in both sisters. At clinical 
examination the first sister had a B2-P2 pubertal stage at the 
age of 17. No spontaneous menarche was registered. The 
second sister had no spontaneous menses, nor a pubertal 
development at the age of 14 (B1, P1). Uterine bleeding was 
induced by graded doses of transdermal estrogens first. 
Addition of progestins in a cyclical administration was given 
thereafter. No symptoms of sex steroids deficiency were 
developed overtime. Olfactometry, MRI, ferritin levels and 
analysis of all other pituitary axes were strictly normal. 
 
The c.869A>T (p.Y290F) GNRHR mutation 
occurred in a girl with nIHH, issued from first cousin parents. 
She reported having had primary amenorrhea, with no breast 
development. At the time of visit she was 22 years old and she 
was already administered with estro-progestins, so that 
evaluation of pubertal stage as well as reproductive organs 
morpho-volumetry resulted uninformative. No olfactory 
impairment was detected by olfactometry. Diencephalic MRI 
did not reveal abnormalities in pituitary region. 
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DISCUSSION 
 
GnRH is universally considered as the key 
player in the neuroendocrine control of the reproductive axis 
(Millar et al., 2004). Phylogenetic studies by several species’ 
comparison indicated the GnRH-receptor couple as ancient as 
500 million years. This couple represents a paradigm for 
understanding not only the reproductive functions, but also for 
the great amount of basic science studies addressed to the 
notions of ligand-receptor interaction and the models 
conceiving receptor desensitization and intracellular signaling 
deciphering.  
GnRH was discovered following pioneer studies conducted 
notably by Geoffrey Harris who showed that pituitary stalk 
interruption in a female rat caused fading of ovarian cycles 
(Green & Harris, 1949). 
In the early seventies, two competing groups published the 
primary structure of LHRH, isolated on the basis of its LH 
releasing activity (Burgus et al., 1971; Matsuo et al., 1971). In 
1976 Roger Guillemin and Andrew Schally shared the Nobel 
Prize for “their discoveries concerning the peptide hormone 
production of the brain”. 
The decapeptide GnRH is processed in hypothalamic neurons 
from a 92 amino acid precursor by enzymatic cleavage and is 
packaged in storage granules that are transported down axons 
to the external zone of the median eminence. The peptide is 
released in synchronized pulses every 60-120 minutes from 
the nerve endings of about 1000 neurons into the hypophyseal 
portal system to stimulate the biosynthesis and the secretion 
of LH and FSH from pituitary gonadotropes. 
The amino acidic sequence of the GnRH receptor was first 
deduced for the mouse receptor cloned from the pituitary αT3 
gonadotrope cell line (Tsutsumi et al., 1992). GnRH receptor 
has the characteristic features of GPCRs. The NH2-terminal 
domain is followed by seven α-helical TM domains connected 
by three extra-cellular domains and three intracellular loop 
domains (Sealfon et al., 1997). The extracellular domains and 
superficial regions of the TMD are involved in peptide binding, 
and the TMD are believed to be involved in receptor 
configuration and conformational change associated with 
signal propagation. The activation of GnRH receptor thus is 
thought to propagate into conformational changes in the 
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intracellular domains involved in G proteins interaction and 
other proteins for intracellular signal transduction. 
A unique feature of the mammalian type-I GnRH receptor is 
the absence of a carboxyl-terminal tail, that is present in all 
other GPCRs and in all of the nonmammalian and mammalian 
type-II GnRH receptors. This is, therefore, a recently evolved 
feature that presumably serves an important role in the 
functioning of the mammalian GnRH receptor. 
 
In this work we conducted a comprehensive 
genetic, clinical and functional study on new variants occurring 
within the GNRH1 and GNRHR genes in order to unravel the 
mechanism of disease in the affected patients, and also to 
better improve knowledge and understanding of ligand-
receptor interactions. The genetic screening revealed ten 
variants within the coding regions of GNRH1 and GNRHR genes 
from 16 different CHH patients (Table 2, Figures 3 and 4). We 
focused on eight individuals with novel or yet uncharacterized 
variants. All these patients but two sisters suffered from nIHH, 
confirming that mutations in GNRH1 and GNRHR determine an 
impairment of GnRH-dependent signaling, without any 
disruption of the migratory route of GnRH neurons, and thus 
without associated phenotypes, notably smell defects. 
 
Patients 1 and 2 (family 1) were affected by 
KS. The nucleotide base change provides a stop codon within 
the decapeptidic sequence of pre-pro-GnRH, completely 
empeding the achievement of a normal neuropeptide. We 
considered that a functional analysis of mutant GNRH1 was 
not needed to demonstrate detrimental effects. Given the 
heterozygous state, we went further on searching for another 
contra allelic event at GNRH1 locus. This was excluded by an 
exhaustive analysis of the entire sequence of intron 1 and of 
the upstream and downstream GNRH1 promoters. A further 
confirmation of the mono allelic event was obtained after 
direct sequencing of PMNC-derived GNRH1 cDNA. Indeed, we 
found the coexistence of WT and W26X transcripts in PMNC 
from peripheral blood. Despite the deleterious character of this 
substitution, there are at least three arguments arguing 
against a causative role in determining disease in these 
individuals. First, the heterozygous state is not in line with a 
causal role for CHH. GNRH1 has been classically associated 
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with an autosomal recessive form of CHH (Bouligand et al., 
2009; Chan et al., 2009). Secondly, the same mutation is 
carried by the unaffected father. Finally, the probands 1 and 2 
are affected by KS, that is in contrast with the obvious 
phenotype of nIHH, as is the case for the GNRH1 mutations 
described to date. In the presence of a normal carrier (father) 
it is unlikely that this mutation might have impaired the 
normal differentiation of GnRH neurons and ultimately 
produced a clinical picture resembling KS. The hypothesis 
most likely complying with the clinical evidence might lie in a 
second genetic event that could have occurred to cause KS in 
this family. It is debatable whether this hypothetical event 
could determine a complete phenotype itself, or might have 
contributed in synergy with the GNRH1 event. Sangers 
sequencing of the main genes associated with KS in women 
(FGFR1, FGF8, PROK2, PROKR2 and WDR11) did not reveal 
abnormalities. It is possible that other genes associated with 
KS, or other not-yet identified genetic events could have acted 
in these patients to determine disease. Next-generation 
sequencing techniques, as well as chromosomal micro-
rearrangements could also be useful to unravel the causes of 
KS in these patients. 
 
For the families 2 and 3 (patients 3, 4 and 5) 
we found the heterozygous R31C GNRH1 mutation. The 
implication of this mutation in determining nIHH was first 
hypothesized by several arguments: first of all, this variant 
segregates with disease in one family and is de novo in the 
other; in addition, at least two previous reports describing 
nIHH cohorts reported the R31C mutation in heterozygosis and 
with an “apparent” dominant inheritance (Chan et al., 2009; 
Quaynor et al., 2011); third, the R31C mutation has never 
been identified in controls. More specifically, this nucleotide 
base change has not been identified in the databases of the 
Exome Aggregation Consortium, 1000 Genomes Project, 
dbSNP, or Exome Variant Server. These findings, together with 
the position of the nucleotide base change within a CpG island 
and the extreme rarity of GNRH1 mutations found hitherto, 
might also suggest for a mutational hot spot. A second contra 
allelic event was excluded by sequencing the regulatory 
regions of genomic GNRH1 and by sequencing the PMNC-
derived cDNA coding regions. We also ruled out oligogenism 
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by sequencing some genes associated with nIHH and Kallmann 
Syndrome (GNRHR, KISS1, KISS1R, TAC3, TACR3, KAL1, 
FGFR1, PROK2, PROKR2). Other genes known to be associated 
with CHH (see Table 1) have not been analyzed. 
The R31C peptide (cys-8) had very low activity in receptor 
binding, SRE-luciferase activation, IP accumulation, Ca2+ 
mobilization, ERK1/2 phosphorylation, lhb gene expression 
and LH secretion. Nevertheless we were unable to 
demonstrate any dominant negative effect on WT GnRH 
activities (further details in (Maione, 2013 #180) appended in 
the appendix section). 
 
In order to further explain disease 
mechanism, we addressed a series of experiments to answer 
to a couple of questions: does the cys-8 mutant have a 
dominant effect over WT passing through the pulsatile activity 
of GnRH and the consequent gonadotrope response? Does the 
pre-pro-GnRH mutated in position 31 have toxic effects on the 
GnRH neuron itself? 
For the first hypothesis, no impairment of WT-induced 
luciferase activity was observed after four pulsatile GnRH-I 
administrations given at 90-minute frequency. Variable 
frequency, amplitude, or longer exposition, not tested in this 
work, might be needed to produce impairment in WT-induced 
signaling. In addition, the rate of GnRH-R expression, known 
to be very low in gonadotrope cells, might influence results 
and impede the evidence of a fine-tuning dysregulation 
(Ballesteros et al., 1998; Finch et al., 2009). The in vitro 
approach thus could not properly reflect the pituitary 
homeostasis and the complex microenvironment studded by 
various molecular and cellular components. Therefore, the 
limits of an in vitro approach in this context, together with the 
negative results of pulsatile assays, prompted us to go further 
and to directly address the second question.  
The second hypothesis is based on a putative toxic effect of 
mutant pre-pro-GnRH, thereby reducing WT GnRH secretion. 
This question is also theoretically sustained by other forms of 
dominant diseases related to neuropeptides developing 
neurotoxic properties after missense mutation, as already 
demonstrated for pro-dynorphin in ataxia (Bakalkin et al., 
2010) or arginine-vasopressin variants in diabetes insipidus 
(Birk et al., 2009). An appropriate cell model to address this 
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hypothesis implies the ability of peptide processing that is 
characteristic of furin-dependent pro-hormone convertase-1 
expressing cells. For this purpose we chose murine Att-20 
cells, able to process pro-opio-melanocortin into the mature 
ACTH and MSH using the same convertase as GnRH neurons, 
and the Gn-11 cells issued from a murine GnRH-
neuroblastoma, endogenously expressing low-levels of murine 
pre-pro-GnRH. Secondly, we had to track protein expression 
by GFP tagging. Finally we developed a R31C pre-pro-GnRH by 
site-directed mutagenesis. The number and the intensity of 
GFP signal was visibly lower after mutant GNRH1 transfection 
than after WT alone. In the absence of other nucleotide 
aberrations after mutagenesis, it is likely that the reduction in 
transfection rate and in GFP intensity could be attributed to 
intrinsic characteristics of the mutant peptide. 
The question about a negative dominance upon WT would 
imply a reduction in GFP signal after co-transfection. 
Expression of WT in combination of R31C at multiple doses did 
not affect the entity or the amount of GFP-positive cells. In 
contrast, co-expression of WT+R31C proteins produced a 
higher GFP signal in all lineages except than in Att-20. It is 
intriguing the hypothesis that the absence of GFP 
overexpression, occurring solely in Att-20, could have 
impaired WT translation in the sole cell type expressing the 
pro-hormone convertase. However, the link between the 
reduction in GFP signal and the putative inability to secrete 
GnRH is not demonstrated, thus remaining elusive. 
Furthermore, cell viability is not impaired in Att-20 cells 
transfected with either WT or mutant GNRH1. The absence of 
repercussions in cell viability comes out against toxic effects of 
R31C mutation, but does not necessarily imply a non-
pathogenic effect.  
Apart from direct or indirect toxic effects, R31C mutation 
might have other harmful properties, such as the suppression 
of a normal protein processing and the secretion of mature 
peptides. In particular, the cysteine in position 31 of the pre-
pro-hormone might favor the formation of disulfide bridges 
within other precursors or with proteins coupled to the 
endoplasmic organelles. Covalent bridges by oxidation of 
cysteines to disulfide bonds may particularly occur in 
compartments with oxidizing environments, such as the 
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endoplasmic reticulum in eukaryotic cells (Darby & Creighton, 
1995). 
In order to investigate this hypothesis, we recently concluded 
a partnership with the Department of Biochemistry (Federico II 
University, Naples). Briefly, supernatants from Att-20, Gn-11 
and 293T cells transfected with WT, R31C or various doses of 
WT+R31C GNRH1 have been collected, passed through a 0.45 
um filter and stored at -80°C. These solutions will be partly 
evaluated by mass spectrometry for quantification of GnRH 
decapeptides (by comparison to the specter generated by pure 
peptides). Part of these solutions will be also employed to 
perform an in-door bioassay. Filtered solutions will be used as 
conditioned media to treat GNRHR-expressing cells in order to 
elicit the main GnRH-dependent cascades. The effects after 
treatment with these supernatants will be compared to those 
observed by pure GnRH peptide administration. 
 
Clinical observations of patients harboring 
the R31C mutation are also striking, and might sustain 
translational research to some extent. Indeed, the presence of 
R31C mutation is always associated with a partial gonadotrope 
deficiency, and thus a normal activation of gonadotrope axis is 
somewhat present in these individuals. The two boys with this 
mutation have normally progressed through the first stages of 
puberty and spontaneous testis enlargement has always been 
observed. In parallel, girls harboring the R31C mutation 
experience menses and may even conceive spontaneously 
(Chan, 2011). This seems to suggest that, at least in a clinical 
setting, a chronic or continuous exposure to the mutant allele 
produces disease overtime. This is of note, since all 
experimental procedures conducted hitherto have been 
performed in bolus, or in a short-course pulsatile manner. 
Apart from in vitro assays, and in the absence of ex vivo 
human surrogates, murine or animal transgenic models should 
be needed to definitely elucidate the pathogenic mechanism.  
 
Patients 6 and 7 from family 4 with nIHH 
carry a homozygous T269M GNRHR mutation. Clinical 
phenotype completely resumes a typical form of familial nIHH 
and is thus consistent with genetic findings. The position 269 
is completely conserved in mammals, and is located in the 6th 
TMD, next to the real end of the third intracellular loop. 
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Changes in position 269 have never been tested from basic 
scientists, and so a prediction of consequences was never 
postulate to date. In silico prediction tools suggested 
damaging consequences. The functional characterization of the 
mutant receptor revealed a complete abolition of GnRH-
dependent signaling, with no elevation of the main 
downstream effectors of signaling cascade. These dramatic 
effects seem to be particularly due to the absence of GnRH 
binding, revealed by competition studies. After subcellular 
protein fractionation, however, the T269M receptor was found 
in the plasma membrane, as revealed by Flag signal. All of 
these experiments, therefore, indicate a complete abolition of 
ligand coupling. 
From a mechanistic point of view, this mutation leads to a 
pituitary disease, with no response to hypothalamic 
stimulation. In clinical settings, in order to restore fertility, 
despite the seminal observations about GNRHR mutations (de 
Roux et al., 1997) the GnRH resistance theoretically abolishes 
the opportunity to use the GnRH pump, that is considered the 
best tool to produce ovulation and limit the occurrence of the 
overstimulation syndrome. Additionally, no chances to 
overcome pathology are envisaged by the utilization of the 
emerging neuropeptides kisspeptin and neurokinin B (Sonigo 
et al., 2012; Young et al., 2013).  
 
The patient 8 from family 5 presents a form 
of nIHH associated with homozygous Y290F mutation in 
GNRHR. The segregation of classical autosomal recessive 
disorder is strongly evoked by the notion that her parents, 
unavailable for genetic testing, were first cousins. The clinical 
phenotype resembles pure nIHH. 
Tyr-290 in TMD 6 is highly conserved among GnRH receptors 
cloned from different species, implying an important role of 
this residue in receptor folding, ligand binding and/or receptor 
activation. Tyr-290 is critical for GnRH I and GnRH II binding. 
Ala substitution of Tyr-290 or changes of residue 5 within 
GnRH decapeptides both led to 82-332-fold reduction in 
affinity (Coetsee et al., 2008; Millar et al., 2004). These data 
are consistent with the direct interaction between the Tyr-290 
of the receptor and the Tyr-5 of GnRH. Studies on I-125-
cetrorelix competition have shown that Y290F decreased 
receptor expression on cell surfaces (Hovelmann et al., 2002). 
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In silico prediction tools indicated damaging effect with high 
likelihood. The functional characterization of Y290F receptor 
mutant reveals a strong impairment in PKC/IP and in MAPK 
signaling, compared to WT. This impairment is partly 
determined by binding reduction, as revealed by competition 
studies, thus confirming the crucial role of Tyr-residue to 
interact with GnRH. 
In clinical settings, this mutation produces a classical form of 
nIHH. The ideal strategy in order to rescue fertility in this girl 
should be to prevent pituitary resistance, as in the previous 
case, and to treat with gonadotropins to stimulate ovulation. 
 
In conclusion, our work expands the 
spectrum of mutations within GNRH1 and GNRHR loci in CHH. 
Functional analyses have contributed to provide novel insights 
in clinical settings as well as in the understanding of the GnRH 
and receptor coupling. The families described throughout this 
report are of great interest for reproductive sciences. In 
addition, the pathophysiology of some clinical pictures, like the 
occurrence of KS in the family 1, or the dominant nIHH in 
families 2 and 3, is not yet explained by in vitro experiments. 
Genetic variants occurring in key-player actors in the 
neuroendocrine control of reproduction are contributing to 
shed more light in this field. The mechanisms by which a 
molecular alteration could unbalance gonadotrope axis 
function and produce disease are of great interest, since a 
wide spectrum of different treatments is now available to 
overcome the molecular alterations challenging fertility. 
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Appendix – the development of a sensorineural test 
applied to CHH. 
 
Patients with CHH usually experience a 
strong detriment of their quality of life owing to the hard 
burden generated by pubertal impairment and lack of steroid 
production, with consequent injury of sexuality in a delicate 
stage of life. Along with repercussions related to gonadotrope 
axis insufficiency, KS patients additionally complain anosmia, a 
serious sensorineural disturbance that further affects choices 
and activities of daily life. nIHH patients share with KS the sole 
endocrine alteration without sensorineural impairment. 
Nevertheless, a subtle reduction of smell function could not be 
excluded by the sole clinical inquiry. The identification of a 
slight smell reduction in a not-otherwise classified CHH 
individual will orientate the diagnostic process more correctly 
towards a formal diagnosis of KS and will provide important 
insights in genetic counseling as well as in the search for 
specific clinical complications. The olfactometry or a 
morphologic study of brain region by Magnetic Resonance or 
CT Scan is thus needed to elucidate and improve a correct 
clinical definition (Maione et al., 2013b).  
During my PhD Course, I had the opportunity to work on the 
characterization of other aspects of sensorineural disabilities in 
CHH patients. Indeed, patients experiencing olfactory loss 
complain flavor disturbance and inability in food identification, 
with serious repercussions on their global quality of life 
(Schiffman, 1997). By contrast, KS patients generally do not 
complain flavor dysfunctions (Hasan et al., 2007). The sense 
of flavor is a complex gustative ability closely related to taste 
and smell integrity, that ultimately allows food recognition, 
oral intake identification and the pleasantness and 
«palatability» of meals. Aim of this study was to explore the 
sense of flavor in KS and in nIHH patients, compared to 
individuals with acquired anosmia and normal controls. Since a 
validated clinical test assessing flavor was not available, an in-
house test has been developed in partnership with GIOTTI 
aromatic manufacturer (Enrico GIOTTI spa, Scandicci, 
Florence, Italy). Of note, this novel sensorineural test has 
been the object of a national patent, identified as Flavor 
Identification Test, application No. FI2014A000229. The details 
of the test, the development and the assessment of reliability 
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and reproducibility are part of an already submitted paper, 
appended to this manuscript.  
Briefly, a series of diluted aromatics were blindly administered, 
and testers were invited to forcedly choose one among several 
possible answers identifying the flavor. The sum of correct 
answers generates a highly-reliable score (Flavor Score).  
Our results have shown an unequivocal and dramatic injury in 
flavor perception in KS, as demonstrated by very low scores 
compared to controls (p<0.0001). This disability resumes what 
observed in acquired anosmics (p=ns) and is not observed in 
nIHH (Fig. 22). Interestingly, KS subjects are not aware of this 
impairment, and their quality of life is consistently higher than 
acquired anosmics with respect to smell disorders, probably 
reflecting the congenital nature of disease. Along with our 
report, we have shown that KS patients fail to identify oral 
intakes.  
Flavor deficiency has now to be accounted as a specific 
sensorineural impairment in KS, whose spectrum of associated 
disabilities is expanding. KS patients should be apprised of 
their gustative inability in order to prevent nutritional 
imbalance and the occurrence of life-threatening accidents. 
 
CHEMOSENSORY 
EVALUATION 
Fig. 1 
SENSORINEURAL  
PERCEPTION 
Odor perception - self assessment
Controls KS nIHH AA
0
5
10
15
Se
lf-
as
se
ss
m
en
t s
co
re
 (1
-1
0)
***
*** ******
Taste perception - self assessment
Controls KS nIHH AA
0
5
10
15
Se
lf-
as
se
ss
m
en
t s
co
re
 (1
-1
0)
Flavor perception - self assessment
Controls KS nIHH AA
0
5
10
15
Se
lf-
as
se
ss
m
en
t s
co
re
 (1
-1
0)
***
***
***
Olfactometry
Controls KS nIHH AA
0
10
20
30
40
50
TD
I s
co
re
***
*** ******
Gustometry
Controls KS nIHH AA
10
12
14
16
18
Ta
st
e 
Sc
or
e
Flavor Identification Test
Controls KS nIHH AA
0
5
10
15
20
25
Fl
av
or
 S
co
re
***
*** *****
A 
B 
C 
D 
E 
F 
 
Figure 22 - Flavor test in controls, KS, nIHH and AA patients. 
Data are reported as individual values plots. On the y-axis is reported 
Flavor Score (range 0-21). KS: Kallmann Syndrome; nIHH: normosmic 
isolated hypogonadotropic hypogonadism; AA: acquired anosmia.  
** p<0.01; *** p<0.001. 
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Abstract
Normosmic congenital hypogonadotropic hypogonadism (nCHH) is a rare reproductive disease leading to lack of puberty
and infertility. Loss-of-function mutations of GNRH1 gene are a very rare cause of autosomal recessive nCHH. R31C GNRH1 is
the only missense mutation that affects the conserved GnRH decapeptide sequence. This mutation was identified in a CpG
islet in nine nCHH subjects from four unrelated families, giving evidence for a putative ‘‘hot spot’’. Interestingly, all the nCHH
patients carry this mutation in heterozygosis that strikingly contrasts with the recessive inheritance associated with frame
shift and non-sense mutations. Therefore, after exclusion of a second genetic event, a comprehensive functional
characterization of the mutant R31C GnRH was undertaken. Using different cellular models, we clearly demonstrate a
dramatic reduction of the mutant decapeptide capacity to bind GnRH-receptor, to activate MAPK pathway and to trigger
inositol phosphate accumulation and intracellular calcium mobilization. In addition it is less able than wild type to induce lh-
beta transcription and LH secretion in gonadotrope cells. Finally, the absence of a negative dominance in vitro offers a
unique opportunity to discuss the complex in vivo patho-physiology of this form of nCHH.
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Introduction
The gonadotropin-releasing hormone (GnRH) is essential in
mammalian reproduction. This decapeptide, released from
hypothalamic GnRH-neurons, triggers an intracellular cascade
involving IP3 accumulation, calcium mobilization and MAPK
phosphorylation through its cognate receptor GnRHR. The
activation of these signaling pathways ultimately stimulates the
synthesis and secretion of gonadotropins (LH and FSH) by
pituitary gonadotrope cells.
The decapeptide sequence is conserved among most mammals
and the amino and carboxyl termini are conserved in mammals
and invertebrates [1–4].
Mutations of the human GNRH1 gene, encoding a 92 amino-
acid pre-pro-GnRH, are a very rare cause of normosmic
congenital hypogonadotropic hypogonadism (nCHH). A frame
shift resulting in a failure to translate the GnRH peptide sequence
gives rise to nCHH with autosomal recessive inheritance [5].
Subsequently a p.R31C GNRH1 mutation in which arginine is
substituted by cysteine has been described [6,7]. This is the sole
mutation affecting the GnRH decapeptide sequence. The arginine
in position 8 of the GnRH decapeptide has been shown to be
crucial for biological activity [2–4] and shown to interact with an
acidic residue in the mouse [8] and in the human [9] GnRH-Rs.
This mutation, though identified in two nCHH families in two
independent series [6,7], has not been characterized. In these
families, the somehow afflicted individuals were heterozygous.
This observation is surprising as the frame shift GNRH1 mutation
only resulted in nCHH in homozygous patients [5].
Here we report on the identification of p.R31C mutation in
three individuals in two additional unrelated nCHH families. All
the individuals are heterozygous for the mutation. We have
undertaken a comprehensive molecular characterization of the
PLOS ONE | www.plosone.org 1 July 2013 | Volume 8 | Issue 7 | e69616
mutation in order to understand the mechanism of nCHH in these
individuals.
Results
Genetic analysis
We identified the GNRH1 c.91C.T (p.R31C) mutation in two
unrelated French families with nCHH. Demographic, clinical,
biological and genetic data are reported in Table 1. Interestingly,
the two pedigrees are very different in terms of presentation
(Fig. 1). In family 1, nCHH is sporadic. The boy (II.1) presented at
19 years old with a failure to progress through puberty. At physical
examination he had a partial pubertal development with 12-mL
bilateral testes volume. He had no olfactory impairment.
Hormone assays revealed very low testosterone levels and low
gonadotropin levels. No secondary causes were found for central
hypogonadism (see Table 1). GNRH1 heterozygous mutation in
this boy was de novo, as ascertained by micro-satellites analysis.
In the second family the GNRH1 mutation was present in
heterozygosis and segregated with disease. The boy (II.1) was
diagnosed having hypogonadotropic hypogonadism because of
small testis volume (10 mL at left, 12 mL at right testis), low serum
testosterone and low gonadotropins. His pubertal stage was P3
according to Tanner. He had no anosmia. Common causes of
secondary hypogonadism were excluded. His mother (I.2) was
affected by primary amenorrhea, and conceived after ovarian
stimulation by exogenous gonadotropins, although a formal
diagnosis was not established at that time. She was re-evaluated
later at the age of 65, and hormone assays revealed low sex steroids
accompanied with inappropriately low gonadotropins. She had no
other apparent secondary causes (see Table 1). The father (I.1) was
not available for genetic analysis.
We did not identify a second genetic event after genomic
regulatory region analysis of GNRH1 locus and GNRH1 cDNA
sequencing in all propositii.
Predictive analysis
The GNRH1 c.91C.T nucleotide substitution did not create
any donor or acceptor aberrant splice site according to prediction
tools with AlamutH software. This nucleotidic substitution induces
a missense at codon 31, replacing Arginine-31 by a Cysteine in the
pre-pro-GnRH (GNRH1 p.R31C).
Figure 1. Pedigree of nCHH families carrying c.91C.T (p.R31[R, C]) GNRH1 mutation. In the family 1, the propositus (II.1) has a de novo
mutation and his filiation has been confirmed by DNA microsatellites. In the family 2 the mutation was transmitted from the mother (I.2) to her son
(II.1). She required medical assistance for procreation. Clinical and demographic data of all patients are reported in Table 1. Electropherogram
represents the heterozygous mutation in the individual II.1 from family 1. In the panel below, pre-pro-GnRH amino acid sequence conservation.
Decapeptide is shown in red.
doi:10.1371/journal.pone.0069616.g001
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Prop v.1.0b predicted that this missense did not abolish
proconvertase-dependent cleavage site for pre-pro-GnRH matu-
ration into the decapeptide (amino-acids 24 to 33).
Alignment with orthologs revealed conservation of arginine in
position 8 of GnRH in mammals (Fig. 1). This amino acid
exchange was classified as deleterious by various in silico prediction
tools (see methods section). More importantly, experiments on the
substitution of arginine 8 with a variety of amino acids
demonstrate that it is crucial for binding and signaling [10].
Arginine 8 was further shown by mutagenesis studies in the
GnRH-R that it interacted with an acidic residue in the
extracellular loop three of the mouse (glutamate 301) and the
human (aspartate 302) GnRH-Rs [8,9].
In vitro molecular characterization
R31C and wild-type (WT) decapeptides were stable over 24-
hours at room temperature in water and culture medium. No
dimerization of the mutant decapeptide was found (Fig. S1).
The R31C GnRH peptide bound the GnRH-R with an affinity
more than 100-fold lower than that of WT GnRH (Fig. 2A and
2B). Dose-response curves with SRE-luciferase assay showed an
almost 100-fold reduction of R31C agonist versus WT (Fig. 3A).
The EC-50 was 4 nM for WT GnRH and 314 nM for R31C
GnRH (p,0.0001, Fig. 3B). ERK1/2 phosphorylation was
maximal at 5 minutes. R31C GnRH showed similar kinetics,
but the degree of phosphorylation was reduced (Fig. 4A).
WT GnRH induced a rapid and transient calcium mobilisation
in LbetaT2 cells. Calcium response by R31C was significantly
reduced compared to WT in terms of peak and area under the
curve (p,0.05, see Fig. 5). Pre-treatment with 100 nM GnRH-
antagonist cetrorelix abolished responses to both ligands (data not
shown). The IP accumulation dose-response curve demonstrated
that the R31C GnRH (EC-50, 199 nM) was more than a 100-fold
less potent than WT GnRH (0.5 nM), (p,0.01, Fig. 6A and B).
The maximal IP generated by both ligands was the same
indicating that the R31C GnRH peptide was a full agonist, as
was found in the SRE-luciferase assay.
WT GnRH significantly increased lhb transcript levels in
gonadotropes (p,0.01), whereas R31C GnRH did not signifi-
cantly increase these levels over baseline (not significant, Fig. 7A).
WT GnRH strongly stimulated LH secretion over baseline
(p,0.001). R31C GnRH significantly stimulated LH secretion in
LbetaT2 cells supernatants over baseline (p = 0.042, Fig. 7B).
The above findings clearly show that in binding, signaling and
functional assays, the R31C GnRH is less potent than WT GnRH.
Since the heterozygous condition was associated with nCHH in
our patients, that could suggest a dominant negative effect, we
studied the effects of combining WT GnRH with R31C GnRH.
We hypothesized that the cysteine in position 8 of the R31C
GnRH might form disulfide bridges with cysteine residues in the
receptor that are not in disulfide bridges. There are three such
cysteines: cysteine 218, cysteine 279 and cysteine 317. In order to
examine this possibility the effects of R31C GnRH pre-incubation
on subsequent binding of a radio-labelled GnRH analog was
examined. We determined from the competition binding study
that R31C GnRH would occupy 50% of receptors. As a control,
we utilized WT GnRH at 1028 M, which also occupies 50% of
receptors. After treatment, the cells were extensively washed to
remove all non-covalently bound peptide. Subsequent binding of
radiolabeled GnRH analog was the same in these treatments as
well as in medium-treated cells (Fig. 2B). These findings indicate
that both WT GnRH and R31C GnRH can be fully removed
from the receptor, indicating that R31C GnRH does not form
covalent disulfide bonds with the receptor.
Dose-response curves generated from SRE-coupled luciferase
were indistinguishable from WT GnRH administered alone
(Fig. 3A).
Table 1. Clinical, biological and genetic characterization of
patients.
II.1
(Family 1)
II.1
(Family 2)
I.2
(Family 2)
Clinical data
Sex M M F
Age at diagnosis 19 21 65
Total testosterone (ng/mL) * 0.8 0.77 NA
Estradiol (pg/mL) * NA 7 ,12
LH (mU/mL) * 1 1 2.8
FSH (mU/mL) * 0,9 1.4 5.8
LH pulsatility NA Absent NA
AMH (mmol/l) * NA 1.4 ,0.4
Inhibin B (ng/mL) * NA 101 ,15
Ferritin (mcg/mL) 63 56 103
Testicular volume (mL) 12 10 -
Ovarian volume (mL) - - ,10
Pituitary and olfactory IRM Normal 3-mm Rathke’s
cyst
Normal
Olfactometry** Normal Normal Normal
Associated features None None None
Genetic data
GNRHR1 normal normal normal
KISS1 normal normal normal
GPR54 normal normal normal
PROK2 normal normal normal
PROKR2 normal normal normal
FGFR1 normal normal normal
FGF8 normal NA NA
NELF NA normal normal
TAC3 normal normal normal
TACR3 normal normal normal
GNRH1 promoter normal normal normal
GNRH1 exon 1 normal normal normal
GNRH1 intron 1 normal normal normal
NA: not available.
*Reference ranges for hormone levels and method characteristics. Total
testosterone: 3.5–8.5 ng/mL for adult men (RIA, Orion Diagnostica device,
SpectriaH, Espoo, Finland; detection limit: 0.01 ng/mL; intra- and interassay
coefficients of variation (CVs): 3.2% and 4.6%); estradiol: 15–35 pg/mL for men,
,16 for post-menopausal women (RIA, Orion Diagnostica, SpectriaH; detection
limit: 2 pg/mL; intra- and the interassay CVs: 2.8% and 5.8%); LH: 1.4–8 mU/mL
for men, .30 mU/mL for post-menopausal women; FSH: 1.4–10 mU/mL for
men, .30 mU/mL for post-menopausal women (for LH and FSH: Immunotech
device, Beckman Coulter, Praha, Czech Republic; detection limits: 0.1 IU/L for
both FSH and LH; intra- and interassay CVs:,6.3% for FSH,,6.7% for LH); AMH:
22–38 pmol/L for men, 14–48 for women (enzyme immunometric assay,
Immunotech reagents, Beckman Coulter Company, Marseille, France; detection
limit: 0.4 pmol/L; intra and interassay CVs: ,12.3% and ,14.2%,); Inhibin B: 80–
327 pg/mL for men, ,20 pg/mL for post-menopausal women (enzyme
immunometric assay, Oxford Bio-Innovation reagents, Serotec, Oxford, UK;
detection limit: 15 pg/mL; intra- and interassay CVs: 4.2% and 10.2%,).
**Subjective olfactometry was performed by a computed-assisted validated test
[35].
doi:10.1371/journal.pone.0069616.t001
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After pulsatile administration of each ligand at 90-minute
frequency, WT GnRH was more potent than R31C GnRH to
induce luciferase activity coupled to SRE reporter gene. Combi-
nation of WT and R31C was not able to impair luciferase activity
when compared to WT alone (Fig. S2).
Treatment of LbetaT2 and GnRH-R-expressing HEK293T
cells with 10 nM WT GnRH in combination with 10 nM R31C
GnRH induced similar kinetics of ERK1/2 phosphorylation
compared to 10 nM WT alone (Fig. 4A). Increasing the dose of
R31C GnRH from 10 nM to 300 nM in the presence of 10 nM
WT GnRH did not reduce ERK1/2 phosphorylation at 5 minutes
exposure (Fig. 4B). Calcium peak and area under the curve after
treatment with the combination of 10 nM GnRH and 10 nM
mutant peptide was indistinguishable from WT GnRH alone
(Fig. 5). IP dose-response curve with equal concentrations of WT
and R31C peptides was indistinguishable from WT GnRH alone
Figure 2. Binding of WT and R31C GnRH to the GnRH receptor (GnRH-R). (A) COS-7 cells were transiently transfected with a human GnRH-R
DNA construct and incubated with a 125I-labeled GnRH agonist in the presence of indicated concentrations of WT GnRH or R31C GnRH. IC-50 values
are WT GnRH, 2.861029 M and R31C GnRH, 8.5061027 M. Data are given as means and SD of two experiments performed in duplicate. (B)
Transfected COS-7 cells were pre-incubated with buffer alone, WT GnRH (1028 M) or R31C GnRH (1025 M) and then washed to allow dissociation of
ligand not covalently attached to the GnRH-R. Pre-incubated cells were then incubated with 125I-labeled GnRH agonist in the absence or presence of
saturating concentration of unlabeled WT GnRH (NSB). Data are the means of two experiments performed in triplicate.
doi:10.1371/journal.pone.0069616.g002
Figure 3. SRE-coupled luciferase assay. (A) HEK293T cells were exposed to graded concentrations of wild type (WT) GnRH, R31C and equimolar
concentrations of WT + R31C during five hours. Luciferase activity arbitrary units by luminometry (a.u.) have been shown as ratio on beta-
galactosidase activity by optical density used as transfection efficiency internal control. This experience was conducted eight times. (B)
Representation of individual values of EC-50 (calculated with Arcsin ‘‘P’’ root transformation) from n=8 dose-response experiments. WT GnRH EC-50
was calculated at 461.2 nM, R31C EC-50 at 3136130 nM. ***p,0.0001.
doi:10.1371/journal.pone.0069616.g003
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(Fig. 6). This indicates that a full range of doses of R31C GnRH
does not influence the ability of WT to bind and activate the
GnRH-R. R31C GnRH was also unable to influence the
stimulation of lhb transcription (Fig. 7A) or LH secretion (Fig. 7B)
from LbetaT2 cells by WT GnRH.
Discussion
GNRH1 mutations are a very rare cause of nCHH [5–7,11,12].
The GNRH1 p.R31C mutation is the only description of an amino
acid change in GnRH. Yet this mutation has been described in
nine individuals in four separate families. This mutation was first
reported in association with nCHH in heterozygosis and a
dominant inheritance was postulated [6], contrasting with the
previously described recessive transmission of the frame shift
mutation, which fails to transcribe the GnRH sequence [5]. Some
nCHH individuals with the R31C mutation concomitantly had
variations in other nCHH genes perhaps suggesting oligogenism.
More recently, the R31C mutation was reported in a girl with no
variations in other nCHH and Kallmann Syndrome-related genes
[7]. This is of interest since this study analyzed all known genes
associated with nCHH and Kallmann Syndrome aiming to
establish the prevalence of oligogenism in these syndromes. This
mutation was considered not sufficient to explain the phenotype
because of the heterozygous inheritance [7]. In the present study,
we have found the same mutation in three additional nCHH
patients from two unrelated families and unrelated to the
previously described families with the R31C mutation. Although
sex steroid and gonadotropin levels undoubtedly related to CHH,
more-than 4 mL testicular volume in patients at presentation
suggested a residual functional activity of hypothalamic-pituitary-
gonadal axis, probably reflecting heterozygosity.
The identification of this recurrent mutation in four unrelated
families, the finding of a de novo event in one family and the
location of the nucleotide base change within a CpG islet are three
consistent arguments for a mutational «hot spot». As interest, this
amino acid is the most variable among vertebrate and invertebrate
GnRHs [1–4]. The R31C GnRH mutation has never been
identified in controls and segregation with the phenotype has been
found in all affected families (see Table 2). Furthermore, this
nucleotide base change has not been identified in 5989 individuals
from the Exome Sequencing Project (ESP) cohort (NHLBI GO,
Seattle, WA; URL: http://evs.gs.washington.edu/EVS; October,
2012). Thus, this implies that this missense mutation is likely
responsible for the nCHH phenotype. However, although the
R31C GnRH had very low activity in receptor binding, SRE-
luciferase, IP, Ca2+, ERK1/2 signaling and in lhb gene expression
and LH secretion, we were unable to demonstrate any dominant
negative effect on WT GnRH activities.
Previous genetic studies established that GNRH1 loss of function
mutations lead to an autosomal recessive nCHH. Thus we first
searched for another genetic event at GNRH1 locus. This was
excluded by an exhaustive analysis of the entire sequence of intron
1 present in the hypothalamic primary transcript, the sequence of
the upstream and downstream GNRH1 promoters and the cDNA
coding regions [13,14]. We also ruled out oligogenism by
sequencing the main genes associated with nCHH and Kallmann
Syndrome [15–17], although WDR11, CHD7 and SEMA3A, other
genes known to be associated with CHH, have not been analyzed.
Furthermore, we cannot entirely exclude the contribution of a
gene not known to be associated with CHH. Next generation
Figure 4. ERK1/2 phosphorylation by Western blot. (A) LbetaT2 cells were starved overnight in serum-free DMEM and then treated by 10 nM
WT, 10 nM R31C, 10 nM WT +10 nM R31C peptides or vehicle for 0, 5, 10 and 30 minutes. Representative of four experiments. Density quantification
is displayed on right-hand, and data are expressed as mean 6 SD for four experiments. *p,0.05; **p,0.01 over baseline. (B) LbetaT2 cells were
starved overnight in serum-free DMEM and then treated by a constant dose of WT GnRH (10 nM) and increasing (0–10–300 nM) doses of mutant
R31C peptide after 5 minutes exposition. Lysates were analyzed by Western Blotting using phospho-ERK1/2 antibodies (Cell SignalingH, open arrow)
and mouse monoclonal anti alpha-tubulin (Sigma AldrichH, St. Louis, MO, close arrow). Similar results on ERK intensity and kinetics were obtained
using transiently transfected HEK293T cells.
doi:10.1371/journal.pone.0069616.g004
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sequencing methods could be helpful to find a possible second
genetic defect.
In order to investigate the possible mechanisms whereby R31C
GnRHmight influence the actions ofWTGnRH, as it is apparently
the case in the patients, we set about first examining the activity of
the R31C GnRH in receptor binding and variety of signaling
pathways, as well as its ability to stimulate LH release. We then
examined its ability to affect WT GnRH actions in these systems.
R31C GnRH had a binding affinity of more than 100-fold lower
than that of WT GnRH. Consistent with this observation, R31C
GnRH had similar reductions in potency (increased EC-50 values)
in stimulation of SRE-luciferase and IP generation.However, R31C
GnRH was able to elicit the same maximal stimulation of SRE-
luciferase and IP, clearly demonstrating that it is a full agonist in
recruiting these signaling pathways. This indicates that it has no
antagonistic activity and it is therefore unlikely to explain the
phenotype of the heterozygous patients. Supporting these observa-
tions, R31C peptide determined weaker responses in contrast to
those of WT GnRH on ERK1/2 phosphorylation, Ca2+ mobiliza-
tion, lhb transcription and LH secretion.
Further studies confirmed our interpretation that R31C GnRH
does not antagonize WT GnRH actions at the receptor level.
When R31C GnRH, at concentrations varying from 10210 M to
1026 M, was added in combination with WT GnRH at 1029 M in
various experiments, it failed to have any impact on receptor
binding, SRE-luciferase, IP generation and Ca2+ signaling or on
lhb transcription and LH secretion. These findings are in
accordance with our understanding of structure-activity relations
of GnRH analogs and their interaction with the GnRH-R.
Arginine 8 is crucial for the correct conformation of mammalian
GnRH and for its binding to the receptor [1–4]. In particular
arginine 8 has been demonstrated to be crucial for the interaction
with the aspartate 302 of the human GnRH-R and the glutamate
301 of the mouse GnRH-R [8,9,18].
The mode of inheritance, apparently dominant in four families,
is thus not explained by a simple negative dominance in the
parameters that we have measured. There are other possibilities
that were not investigated here. Firstly, the mutant peptide may
interact with molecules within the GnRH neuron to impair
activity or induce toxicity, thereby reducing WT GnRH secretion.
Aberrant transcription products might be retained in the
endoplasmic reticulum or could act as neurotoxic agents, as
already demonstrated for pro-dynorphin in ataxia [19] or
arginine-vasopressin variants in diabetes insipidus [20]. Another
Figure 5. Effect of treatments on intracellular calciummobilization. Cells were loaded with Fura 2-AM. At the time of the experiment 100 mM
EGTA was added 30 sec before addition of 300 mM of CaCl2 (Ca2+) to the medium as indicated, and cells were then stimulated with 10 nM of wild
type (WT), mutant (R31C) or equimolar combination (10 nM WT +10 nM R31C) or vehicle for 3 min. In the upper panel, representative curves of single
cell recording. Each experiment mean was analysed using One-way ANOVA followed by Tukey’s Multiple comparison test. In the lower panels,
histograms show the means 6 SEM (n= 4) of the response to ligands as calcium peak and as area under the curve (AUC). R31C-induced peak and
AUC were significantly lower than WT. Combined treatment by WT+R31C did not induce a different calcium peak and AUC compared to WT alone.
Representative of at least three independent experiments, *p,0.05.
doi:10.1371/journal.pone.0069616.g005
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possibility is that, in GnRH neurons, the R31C GnRH precursor
forms an aberrant intermolecular disulfide bridge with the WT
GnRH precursor, which disrupts correct folding of the molecule
leading to detection by surveillance proteins and trafficking to
lysosomes for degradation of both peptides. In addition, the
heterodimer may be resistant to processing.
Although a wide range of cellular models was used, they do not
necessarily reflect in vivo events. Despite abundant literature, the
molecular mechanisms underlying GnRH-R down-regulation and
pulse deciphering remain currently poorly understood [21–23]. It
is of note that SRE-luciferase activity was not impaired after four
pulses at 90-minute frequency (Fig. S2). Nevertheless a slow and
progressive loss of pituitary response to mutant GnRH might
require a longer pulsatile exposure. In this context, a transgenic
mouse model may shed light on the mechanism of the dominant
negative effect [24].
In conclusion, together with our report, four nCHH families
carrying R31C GNRH1 heterozygous mutations have been
identified. As this is a putative «hot spot» mutation it is likely to
be identified in other nCHH families. The families harboring the
R31C mutation are of great interest for reproductive sciences since
the pathophysiology is not explained by in vitro experiments. There
is herein an obvious opportunity to study novel aspects of GnRH
signaling in vivo and/or to identify novel genes modulating GnRH
reproductive function.
Materials and Methods
Patients
From a cohort of 410 patients with congenital hypogonadism
we screened for a panel of mutations including GNRH1 (see
below). The study was approved by the Paris Sud University
Hospital ethics committee and complied with human research
guidelines as stated in the Declaration of Helsinki. Patients gave
their written informed consent before genetic analysis and
hormone studies.
Hormone assays
Serum LH, FSH, inhibin B, plasma testosterone and estradiol
concentrations were measured by immunoradiometric, enzyme-
linked immunoabsorbent, or radioimmuno-assays [25] as reported
in Table 1.
Genetic testing
Genomic DNA was isolated from white blood cells (WBC).
Direct genomic sequencing of GNRH1 was performed by
sequencing all exons and exon-introns junctions (NG_016457.1),
up-stream and down-stream promoter encompassing 1100 bp
before start site of transcription (Fig. S3). Direct genomic
sequencing of coding exons and intron-exon junctions of
GNRHR1, KISS1, GPR54, NELF, TAC3, TACR3, FGF8, FGFR1,
PROK2 and PROKR2 was performed as previously described [26].
PCR primers were designed by Primer Blast (http://www.ncbi.
nlm.nih.gov/tools/primer-blast/) [26]. PCR and sequencing
products were purified on a Biomek NXP-96 Laboratory
Automation Workstation (Beckman Coulter, Villepinte, France)
with Agencourt Ampure XP and Agencourt Cleanseq (Beckman
Coulter Genomics, Danvers, MA). Sequencing products were
analyzed with an automated capillary sequencer (ABI PRISM
3130xl Genetic Analyzer; Applied Biosystems, Foster City, CA).
Electropherogram-derived sequences were compared with NCBI
references using SeqScape Software 2.6 (Applied Biosystems,
Foster City, CA).
Figure 6. IP accumulation. (A) COS-7 cells were transiently transfected with human GnRH-R expression vector and washed before the addition of
myo-[2-3H]Inositol. After 16 hours cells were washed and incubated for 1 hour with graded concentrations of WT, R31C and equimolar WT+R31C
GnRH. This experience was conducted three times each in triplicate. (B) Representation of individual values of EC-50 (calculated with Arcsin ‘‘P’’ root
transformation) from n= 3 dose-response experiments. WT GnRH EC-50 was calculated at 0.5260.22 nM, R31C EC-50 at 198.8675.9 nM, WT+R31C
EC-50 at 0.6360.42 nM.
doi:10.1371/journal.pone.0069616.g006
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Microsatellites genotyping was performed to confirm filiation
(Powerplex 16 SystemH, Promega, Madison, WI).
Total RNA was extracted from cells (WBC or cells in culture)
with the TrizolH reagent (InVitrogen, Cergy Pontoise, France).
RT-PCR and direct cDNA sequencing was performed as
previously reported [26,27]. Complete CDS of GNRH1 transcripts
(NM_0001083111.1 and NM_000825.3) were analyzed with
primers for RT-PCR and sequencing in Table S1.
Molecular Characterization of the GnRH R31C mutant
Peptide custom and stability. ‘‘Wild type’’ (pGlu-His-Trp-
Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2) and ‘‘R31C’’ (pGlu-His-Trp-
Ser-Tyr-Gly-Leu-Cys-Pro-Gly-NH2) mutant GnRH were synthe-
sized by a custom peptide manufacturer (EurogentecH, Lie`ge,
Belgium). Molecular weight was confirmed by MALDI-TOF and
purity was assessed at ,95% by the manufacturer.
Lyophilized products were suspended in sterile water in order to
obtain 0.1 mM aliquots and conserved frozen at 2150uC.
LC-MS/MS was performed with Quattro-LCZ triple quadru-
pole mass spectrometer equipped with the orthogonal electrospray
source (Micromass,Manchester, UK) to analyze peptides stability in
solution. Peptides solutions (water and cell culture medium) were
incubated 24-h at room temperature for these stability studies.
In silico prediction of peptide cleavage was performed by means
of Prop v.1.0b ProPeptide Cleavage Site (http://www.cbs.dtu.dk/
services/ProP).
Prediction of protein function after selective amino acid
substitution was obtained by means of AlamutH (Interactive
Biosoftware, Rouen, France), AlignGVD (http://agvgd.iarc.fr/
agvgd_input.php/), Polyphen2 (http://genetics.bwh.harvard.edu/
pph2/), SIFT (http://sift.jcvi.org/) and PANTHER Coding SNP
Analysis tool (http://www.pantherdb.org/tools/csnpScoreForm.
jsp).
Cell lines
Various cell lines were used for the experiments. HEK293T
(ATCC CRL-11268) and COS-7 (ATCC CRL-1651), which do
not express GnRH-R, were used after transient transfection with
expression vector of human GNRHR (Missouri S&T cDNA
Resource Center, Rolla, MO). Murine gonadotrope LbetaT2
cells were kindly provided by Dr. Mellon laboratory [28]. These
cells endogenously express GnRH-R and are able to express
gonadotropin subunit transcripts and to secrete mature LH
glycoprotein after GnRH treatment [28].
Competition radioligand binding assays
The high affinity GnRH analog, [His5, D-Tyr6]-GnRH was
radio-iodinated as previously described [29] and purified using
Sephadex chromatography [30]. COS-7 cells were transiently
transfected with a human GnRH-R DNA construct containing the
human GnRH-RII carboxy-terminal to enhance expression [31]
using 6 mg of DNA and 30 ml FuGene HD (Promega Corporation,
Madison, WI) per 10 cm dish and seeded into 12-well plates. Two
days after transfection cells were washed with HEPES-DMEM
containing 0.1% bovine serum albumin (261 ml, HEPES-
DMEM-BSA) and incubated with 125I-[His5, D-Tyr6]-GnRH
(100,000 CPM per well) and various concentrations of WT GnRH
or R31C GnRH (4 h, 4uC) in a total volume of 0.5 ml. Cells were
washed with phosphate-buffered saline (261 ml) and lysed with
NaOH (1 ml, 0.1 M). Cell-bound radioactivity was counted in a
gamma counter and IC-50 values were calculated using Graphpad
Prism (GraphPad Software Inc, San Diego).
To determine whether R31C GnRH binds covalently to the
GnRH-R, transfected COS-7 cells were incubated with WT
GnRH (1028 M), R31C GnRH (1025 M) or HEPES-DMEM-
BSA alone (2 h, 4uC), washed with HEPES-DMEM-BSA (1 ml)
and incubated in HEPES-DMEM-BSA (5 ml, 1 h, 4uC) to allow
Figure 7. Effects of treatments on lhb transcription and LH
secretion. (A) LbetaT2 cells were starved overnight in serum-free
DMEM and treated either by 10 nM WT, R31C, 10 nM WT +10 nM R31C
peptides or vehicle. After five hours treatment cells were lysed for RNA
extraction (TrizolH). Mouse lhb levels were analyzed by quantitative real
time RT-qPCR. Values are expressed as individual ratios on 18S and
represented as fold induction on vehicle as means 6 SEM, **p,0.01.
This experience was conducted n= 7 times in duplicates. (B) LH
concentrations from LbetaT2 cells culture media. Cells were starved
overnight in serum-free DMEM and incubated with 10 nM WT, 10 nM
R31C, 10 nM WT +10 nM R31C, or vehicle for 5 hours. LH levels were
measured by a combined rat/mouse RIA. Values are expressed as
individual values and as means 6 SEM, *p,0.05, ***p,0.001. The
experiment was conducted four times and each sample was assayed in
duplicates.
doi:10.1371/journal.pone.0069616.g007
Table 2. Recurrence of c.91C.T (p.R31C) GNRH1 base change
in subjects from CHH families and in healthy controls.
Authors Reference Year CHH
Healthy
individuals
Vagenakis et al. [11] 2005 0/26 NA
Chan et al. [6] 2009 4/310 0/192
Topaloglu et al. [36] 2009 0/50 0/100
Quaynor SD. et al. [7] 2011 2/48a 0/188
Current study 2013 3/410b 0/545b
Total 9/844*** 0/1025
NA: not applicable; *** p,0.0001 by Fisher’s test between CHH patients and
healthy controls. a: the mother of the female propositus has been represented as
a carrier but no clinical data are reported. b: 120 CHH patients and 345 healthy
subjects have been added to previously published data [5].
doi:10.1371/journal.pone.0069616.t002
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dissociation of non-covalently bound peptide, before the binding
assay was performed as above.
Serum Responsive Element (SRE) luciferase assay
luc2P/SRE/Hygro plasmid (Promega, Madison, WI) was used
to test luciferase production in response to MAP kinase activation
as a reporter gene system. HEK293T cells (1.26104 cells/well)
were seeded 72 h before testing in high-glucose Dulbecco’s
minimal essential medium (DMEM, Invitrogen, Cergy Pontoise,
France) containing 2 mM glutamine, 100 IU/mL penicillin,
100 mg/mL streptomycin, and 10% heat-inactivated fetal calf
serum at 37uC in 96-well plates. Twenty-four hours before
testing, cells were co-transfected in serum free OptiMEM, using
Lipofectamine 2000 (Invitrogen, Cergy Pontoise, France) with
the plasmids for human GnRH receptor, luc2P/SRE/Hygro and
pMIR-REPORTTM beta-galactosidase vector (Applied Biosys-
tems, Foster City, CA). WT GnRH, R31C, WT+R31C or
vehicle were added at different dilutions (from 10210 to 1026 M).
After 5 h-incubation cells were harvested and assayed for
luciferase activities as previously described [32], using a
luminometer (Victor, Perkin Elmer, Waltham, MA). To stan-
dardize for transfection efficiency, the relative light units were
normalized by the galactosidase activity at optical density. EC-50
and Emax values were calculated using Graphpad Prism
(GraphPad Software Inc).
Inositol phosphate (IP) accumulation
COS-7 cells were transiently transfected by electroporation with
human GnRH-R DNA (10 mg/15 cm dish), seeded into 12-well
plates and radiolabelled by overnight incubation with myo-
[3H]Inositol (0.5 mCi/well, American Radiolabeled Chemicals, St
Louis,Mo).Radiolabelled cells werewashed and incubated (30 min,
37uC) in IP medium (HEPES-DMEM-BSA supplemented with
10 mM LiCl), then stimulated (60 min, 37uC) with various
concentrations of WT GnRH or R31C GnRH or equal concentra-
tions ofWTGnRHandR31CGnRH. Incubations were stopped by
removal of the medium and cells were lysed by addition of formic
acid (1 ml, 10 mM). IP were extracted from cell lysates usingDowex
1 X8-200 chromatography and counted using a liquid scintillation
counter (Pack ard). EC-50 and Emax values were calculated using
Graphpad Prism (GraphPad Software Inc) [33].
ERK1/2 Western blot
LbetaT2 cells were starved 18 h in serum-free DMEM before
treatments, then exposed to 10 nM of WT, 10 nM of R31C, the
combination of 10 nM of each peptide or vehicle. Cells were
harvested at 0, 5, 10, 15 and 30 minutes after treatment. Western
blotting analyses were performed as previously described [32].
Measurement of intracellular free calcium concentration
([Ca2+]i)
LbetaT2 cells were kept in serum freemediumovernight and then
loaded with 2 mM Fura2-AM for 45 min at 37uC. The experiment
was conducted in HEPES buffer (in mM; 116 NaCl, 5.6 KCl, 1.2
MgCl2, 5 NaHCO3, 1 NaH2PO4, 20 HEPES ph 7.4) in presence of
extracellularCa2+ (EGTA100 mM+CaCl2 300 mM). Single images
of fluorescent emission at 510 nm under excitation at 340 and
380 nm were taken every 5 Sec. Changes in [Ca2+]i in response to
GnRHs were monitored using the Fura2 340/380 fluorescence
ratio. Basal ratio was arbitrarily considered as 1. Ca2+ responses over
basal level were given either as maximal rise of [Ca2+]i or as area
under the curve (for 2 min after agonist addition).
Gene expression study
LbetaT2 cells were grown at 106/well in 6-well plates and
starved in serum-free DMEM 18 h before tests. After 5 hours
incubation with 10 nM WT, R31C, the combination of 10 nM
WT +10 nM R31C peptides or vehicle, cells were washed with 16
PBS and total RNA isolated using TrizolH (Invitrogen, Germany).
Lhb (murine LH beta subunit) transcript was quantified by real-
time RT-PCR, using an ABI Step One Sequence Detector
(Applied Biosystem, Foster City, CA) as previously described [27].
Primers are provided in Table S1.
LH assay
LbetaT2 cells were starved overnight in serum-free DMEM.
The test day cells were exposed to 10 nM WT, R31C, the
combination of 10 nM of each peptide or vehicle during five
hours. Cell culture supernatants were collected and rapidly stored
at 280uC. In cell culture media, LH concentration was measured
using a previously described ELISA method [34] with reagents
supplied by Dr. Parlow (National Hormone and Peptide Program,
Harbor-UCLA Medical Center, Torrance, CA). The minimum
detectable LH concentration was 0.2 ng/ml, and the interassay
coefficient of variation was less than 10%.
Statistical analyses
Only nonparametric tests were used. Friedman’s test was used
to compare three or more matched groups and Kruskall-Wallis
test for unmatched groups. These analyses were followed by
Dunn’s post comparison test. Differences were significant when
p,0.05 (*p,0.05, **p,0.01, ***p,0.001). Statistical analyses
were performed using GraphPad Prism version 5.0d (GraphPad
Software Inc., San Diego, CA).
Supporting Information
Figure S1 Peptide stability on mass spectrometry-
coupled electrospray (Quattro-LC). Peptides were measured
in aqueous solution at pH 7 and starved overnight at 37uC. WT
and R31C decapeptides are found at the expected molecular
weights (1181.6 and 1128.5, respectively). Formation of smaller
fragments was absent in WT and negligible in R31C. Formation of
R31C dimers was absent.
(PPT)
Figure S2 Luciferase activity after pulsatile exposure.
HEK293T cells were transiently transfected with GNRHR and
SRE-coupled luciferase reporter gene, and then exposed to four
90 min-spaced pulses of 10 nM WT, 10 nM R31C and
10+10 nM WT+R31C. After 5 minutes exposure to each ligand,
cells were washed, and a subsequent pulse was given 90 minutes
after. Five hours after the last pulse, cells were harvested for
luciferase assay. Luciferase activity arbitrary units obtained by
luminometry (a.l.u.) are shown as ratio on beta-galactosidase
activity by optical density (used as transfection efficiency internal
control). This experience was conducted three times (n = 8
replicates for each experiment).
(PPT)
Figure S3 Genomic localization of human GNRH1 and
related transcription and translation products. Two main
regulatory regions are located upstream the trascription start site:
the proximal promoter mainly regulates hypothalamic trascript,
whereas the distal promoter controls a longer GNRH1 transcript
(retaining entire intron 1 sequence) in the extra-cerebral tissues.
Amino acids are represented by letters from the international
nomenclature. In the prepropeptide GnRH, functional domains
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are represented for the signal peptide (23 amino acids, blue),
decapeptide GnRH (purple), and GnRH-associated peptide (GAP)
(56 amino acids, green) (adapted from Bouligand et al., NEJM,
2009).
(PPT)
Table S1 Primer sets used for experiments.
(DOC)
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Dear Editor, 
Please find enclosed the manuscript entitled “Flavor impairment: a neglected sensorineural 
disability in patients with Kallmann Syndrome” by Maione et al. 
This is the first report focusing on flavor function in patients with Kallmann Syndrome, a rare 
endocrine disease affecting gonadotrope axis as well as olfaction.  
 Along with this Research Article, we demonstrate that patients with Kallmann 
Syndrome, though unaware of flavor disability, fail not only to detect volatile compounds 
(anosmia) but also to identify orally-administered aromatic solutions (flavor) when compared 
to patients with normosmic hypogonadism and controls. This disability resembles what is 
observed in acquired anosmics, who complain a marked inconvenience of flavor and perceive a 
remarkable handicap in relation to this impairment.  
The sense of «flavor» is complex, and involves every aspect of the routinely life, holding a very 
high impact on the general wellbeing and health. The social and relational aspects of foods and 
mealtimes, the economic and cultural repercussions related to flavor represent an original and 
in our opinion interesting investigation. The finding of a newly misdiagnosed sensorineural 
impairment in these patients might be of crucial importance for scientific community and for 
physicians who usually take care of these patients.  
Finally, the disclosure of this injury has enabled us to develop and standardize a new clinically-
relevant chemosensory test with high reliability, whose results are offered for the first time in 
this manuscript. 
We trust in scientific consistence not less than originality of this work and thus we look forward 
to hearing from your opinion. We sincerely think these contents meet your Journal’s scope.  
 The authors hereby confirm that neither the manuscript nor any part of it has been 
published or is being considered for publication elsewhere. By signing this letter each of the 
Authors acknowledges that he or she participated sufficiently in the work to take public 
responsibility for its content. 
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ABSTRACT 38 
 39 
Background. Kallmann Syndrome (KS) associates congenital hypogonadism to olfactory 40 
impairment. Our aim was to evaluate flavor function and flavor-related handicap in KS patients. 41 
Patients and Methods. 30 patients with KS, 12 with normosmic hypogonadism (nIHH), 24 with 42 
acquired anosmia (AA) and 58 healthy controls entered the study. All participants filled 43 
questionnaires for dietary habits, olfaction-related quality-of-life, and self-determined smell, flavor 44 
and taste abilities prior to undergo standardized olfactometry and gustometry. Each subject 45 
underwent flavor test, developed with orally-administered aqueous aromatic solutions, consisting in 46 
identifying 21 different compounds by choosing each out of five alternative items. Flavor score (FS) 47 
was calculated as the sum of correct answers (range 0-21). 48 
Results. Flavor perception by self-assessment was similar between KS, nIHH and controls, and 49 
was largely reduced in only AA. FS was similar between KS (5.4±1.4) and AA (6.4±1.9), and lower 50 
than nIHH (16.2±2.4,p<0.001) and controls (16.8±1.7,p<0.0001). FS showed strong reproducibility 51 
and correlated with olfactory scores in the overall population. KS and AA patients identified 52 
aromatics eliciting trigeminal stimulation better than pure odorants. Olfaction-related quality-of-life 53 
was more impaired in AA than in KS. 54 
Conclusions. This is the first report showing flavor impairment in KS. This contrasts with what 55 
generally evidenced in routinely clinics, since KS patients, contrarily to AA, do not complain flavor 56 
inability, perhaps owing to the congenital nature of dysfunction. Flavor injury should be accounted 57 
as a specific KS impairment, because of important detrimental effects on physical and mental 58 
health and on quality-of-life. KS patients might be apprised of flavor inability also to prevent 59 
unexpected and life-threatening accidents. 60 61 
 3 
BACKGROUND 62 
 63 
Kallmann syndrome (KS; MIM 308700, 147950, 244200, 610628, 612370, 612702) is defined by 64 
the association between congenital hypogonadotropic hypogonadism (CHH) and olfactory 65 
dysfunction (1, 2).  66 
Gustative abilities are poorly evaluated in KS patients. Basic taste evaluated with 67 
electrogustometry has been found normal in KS (3). The sense of flavor is a complex gustative 68 
ability closely related to taste and smell integrity, that ultimately allows food recognition, oral intake 69 
identification and the pleasantness and «palatability» of meals. Patients experiencing olfactory 70 
loss, rather than lone olfactory impairment, mainly complain flavor disturbance and inability in food 71 
identification, with serious repercussions on their global quality of life (4). In contrast, KS patients 72 
generally do not complain gustatory or flavor dysfunctions (3). 73 
Aim of this study was to explore the sense of flavor in KS patients, in comparison to patients with 74 
congenital normosmic isolated hypogonadism (nIHH), those with acquired forms of anosmia (AA), 75 
and normal healthy controls. 76 
 77 78 
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MATERIAL AND METHODS 79 
 80 
Patients 81 
The present study was approved by the Local Ethics Committee (Comitato Etico Università 82 
Federico II, related reference number 253/13). All the participants were adult and gave their written 83 
informed consent, in keeping with Italian Bioethics Law and the Declaration of Helsinki. 84 
30 patients with KS, 12 with nIHH, 24 with AA, and 58 normal subjects entered the study. Criteria 85 
for inclusion of KS patients included: 1) congenital hypogonadotropic hypogonadism, defined by 86 
clinical signs or symptoms of hypogonadism and: in men, serum testosterone levels below 1 ng/mL 87 
in the presence of low or normal gonadotropins; in women, primary amenorrhea and estradiol 88 
levels below 20 pg/ml in the presence of low or normal gonadotropins; 2) complete anosmia, as 89 
assessed by a previous olfactory test, or defined by self-report; 3) otherwise normal biochemical 90 
tests of anterior pituitary function and ferritin concentrations. nIHH was defined by the same criteria 91 
as KS except for olfactory impairment. AA was due to trauma (n=3), chronic nasal disease such as 92 
rhinosinusitis with or without polyps (n=7), viral infections (n=5), tumors (n=2), previous surgery 93 
(n=5) or unknown causes (n=2). Subjects with neurodegenerative disorders were excluded. 94 
Healthy controls had neither smell impairment nor reproductive disease at clinical enquiry, and 95 
were enrolled by participating at an educational and medical prevention program campaign 96 
(Campus Salute Onlus, Naples, Italy; www.campussalute.it). We excluded all controls having 97 
current or chronic sinusopathies, nasal polyps, viral or seasonal rhinitis, and those suffering from 98 
either neurodegenerative or ascertained cognitive disorders. We also excluded individuals being 99 
administered drugs known to interfere with taste or smell abilities (anti-thyroidal, antibiotics, 100 
griseofulvin, lithium, penicillamine, procarbazine, rifampin, anxiolytic, antipsychotic, antiepileptic, 101 
antidepressants, amiodarone, digoxin, statins, chemotherapic drugs). Characteristics of the sample 102 
population are summarized in Table 1. 103 
Food intake was restricted to drinking water within 3 hours before the tests. Alike, smoking was not 104 
allowed within the same time period. 105 
 106 
Questionnaires  107 
Prior to the evaluation of chemosensory functions, patients and controls were invited to self-define 108 
their ability in sensorineural perception. Each participant assessed olfaction (smell ability), flavor 109 
(food and oral intakes identification ability) and taste (basic taste ability) by means of a color-110 
intuitive ten-grade arbitrary scale ranging from 0 (minimum) to 10 (maximum). In order to evaluate 111 
dietary habits, patients and controls were submitted to the PREDIMED questionnaire, whose 112 
scores range from 0 to 14 (5). High scores mostly comply with Mediterranean diet style and related 113 
food preference. All participants filled the questionnaire for olfactory disorders (QOD) that is 114 
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particularly designed for anosmic populations. High QOD scores denote strong detriment of 115 
olfactory related quality of life (6). 116 
 117 
Smell test 118 
All the subjects were submitted to the Sniffin’ Sticks® test (SS-Burghart Medical Technology, 119 
Wedel, Germany), in which odorants are presented in felt-tip pen-like sticks. The test consisted of 120 
three subtests for the study of odor threshold (T), odor discrimination (D), and odor identification 121 
(I), respectively, as well described by Hummel et al. in 2007 (7). 122 
Each subtest result was then summed up to a composite score, known as TDI score. Anosmia has 123 
been defined by a TDI<16, while normosmia, according to the subjects’ age, by a TDI>29 for the 124 
subjects between 18 and 53 years, and by a TDI>28 for those older than 53. 125 
 126 
Taste function  127 
Basic gustatory test has been extensively described by Pingel et al. (8). Four tastants were tested: 128 
1) 10 g/L (29 mM) sucrose, for the «sweet»; 2) 324 mg/L (1 mM) quinine hydrochloride, for the 129 
«bitter»; 3) 1.0 g/L (0.017 M) sodium chloride, for the «salty»; 4) 0.2 g/L (1 mM) citric acid, for the 130 
«sour». 131 
These substances were soluted in distilled water and administered regionally. A drop of 132 
approximately 20 microliters of each solution was applied on the upper surface of the tongue 133 
Before application of each taste solution, the mouth was rinsed twice with distilled water. After 134 
presentation of the stimulus each patient or control was invited to pick one of the five descriptors 135 
(“sweet”, “sour”, “salty”, “bitter”, or “water/no taste”). The Taste Score was calculated as the sum of 136 
correctly identified tastants and ranged from 0 to 16. Hypogeusia was defined for a TS <13 (8). 137 
 138 
Flavor test 139 
The flavor test was developed in aqueous solutions containing aromatic extracts, kindly provided 140 
by GIOTTI manufacturer (Enrico Giotti spa, Scandicci, Firenze, Italy). Each compound was 141 
previously tested and marketed for alimentary use according to Italian and EU current regulations 142 
(European Food Safety Authority Regulation EC n. 178/2002; EC n. 854/2004; Italian G.U. n. 143 
139/2004). A series of 20 extracts has been selected in accordance to the routinely dietary use. 144 
More details on aromatic bases employed for the current test are reported in Supplemental Table 145 
1. Each tastant, originally contained in a 30-mL amber bottle, was diluted in purified water 146 
according to manufacturer’s instructions, stored at 4°C in aliquots for mono-usage after preparation 147 
and maintained at room temperature 20 minutes before administration. An aliquot of approximately 148 
1 milliliter of each tastant was administered in oral cavity through a Pasteur pipette and maintained 149 
approximately five seconds; mouth was then rinsed twice with purified water before the 150 
administration of the following tastant. At each administration, participants were invited to identify 151 
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the aromatic by forcedly choosing the correct solution among five proposed items. A total of 21 152 
aromatics (including one blank) were sequentially administered. The flavor score (FS) was 153 
calculated as the sum of correctly identified aromatics and ranged from 0 to 21. The flavor test has 154 
been deposited for patent license (application patent No. FI2014A000229). 155 
 156 
Statistical analyses 157 
Data are reported as mean ± standard deviation (SD) and as individual values in the figures. The 158 
non-parametric ANOVA Dunn’s test was used to compare quantitative data across the KS, nIHH, 159 
AA and control groups. The χ2 test and Fisher’s exact test were used to compare categorical data. 160 
Spearman’s rank was applied to define correlations, and Bland-Altman plots and linear regression 161 
to assess reproducibility. Differences were considered statistically significant at p<0.05. Univariate 162 
and multivariate analyses using logistic regression models were conducted to identify determinants 163 
of flavor function scores. Statistical analyses and graphics were performed using Prism software, 164 
version 5.0f (GraphPad Software Inc., La Jolla CA) and the SPSS 16.0 package (SPSS, Inc., 165 
Chicago, IL). 166 
 167 168 
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RESULTS 169 
 170 
Patients with AA were older than KS, nIHH and controls (p<0.01 versus all) and had higher BMI 171 
than controls and KS (p<0.01 and p=0.026, respectively). No difference in age and BMI was found 172 
across KS, nIHH and controls. Population characteristics are given in Table 1. 173 
Sensorineural perception 174 
Odor perception by self-assessment was impaired at similar extent in KS and AA patients. It was 175 
consistently lower in anosmics (KS and AA) than in both controls (p<0.0001) and nIHH (p<0.0001, 176 
Fig. 1A). Taste perception by self-assessment was similar across the four groups (Fig. 1B). Flavor 177 
perception was not different between KS, nIHH and controls. On the contrary, AA patients reported 178 
lower flavor perception than controls, nIHH and KS (p<0.001 for all, Fig. 1C). 179 
Chemosensory evaluation 180 
KS and AA patients resumed similar TDI scores on olfactometry (9.4±2.1 vs 9.7±2.7, respectively, 181 
p=0.62). TDI scores in KS and AA were consistently lower than either nIHH (36.3±5.6, p<0.001 for 182 
both) or controls (37.2±4.3, p<0.001 for both, Fig. 1D). Significance did not change after analysis of 183 
each subtest (threshold, discrimination and identification) taken separately.  184 
Taste Score by gustometry was not different across KS (15.1±1.2), nIHH (15.8±0.6), AA (15.1±1.2) 185 
and controls (15.2±1.3, see Fig. 1E). Mild hypogeusia was found in 3 controls, 1 KS and 1 AA 186 
patient (p ns). 187 
FS was dramatically lower in KS (5.4±1.4) than in nIHH (16.2±2.4, p<0.001) and in controls 188 
(16.8±1.7, p<0.0001). No difference was found between KS and AA (6.4±1.9, p=ns) (Fig. 1F). 189 
Differences in FS did not change after adjustment for age and BMI. A strong correlation was found 190 
between TDI and FS scores in the entire population (r=0.89, p<0.0001, Fig. 2A). Nonetheless, 191 
correlation was abrogated when considered the anosmic (AA+KS, Fig. 2B) and the normosmic 192 
(controls+nIHH, Fig. 2C) populations separately. 193 
Univariate analysis in the overall population showed that FS score correlated with gender (r=0.4, 194 
p<0.0001), odor self-assessment (r=0.86, p<0.0001), QOD – Quality of Life (r=0.77, p<0.0001) and 195 
TDI (r=0.94, p<0.0001) scores. Correlations remained significant after adjustment for gender. After 196 
adjustment for TDI score, only odor self-assessment score still held significance (r=0.52, p=0.039). 197 
Univariate analysis in KS population showed that FS score was inversely related to QOD – Quality 198 
of Life scores (r=-0.78, p 0.013), whereas TDI scores did not correlate with QOD items. 199 
Unlike controls and nIHH, KS and AA patients were more able to identify aromatics with property to 200 
elicit a trigeminal response than those with a pure olfactory action (p<0.0001 and p<0.01, 201 
respectively, Fig. 3). Nevertheless, the ability in identifying compounds with trigeminal action in KS 202 
and AA was weaker than in controls (p=0.028). 203 
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Test/re-test analyses revealed strong reproducibility at both normosmic and anosmic ranges 204 
(Supplemental Fig. 1).  205 
All populations resumed similar PREDIMED scores (Table 1). When analyzing details for food 206 
preference, however, AA seemed to consume more frequently legumes and nuts ’ servings than 207 
controls (Supplemental Table 2). 208 
QOD – Quality of Life score was higher in AA than in controls (p<0.0001), in nIHH (p<0.0001) and 209 
in KS (p<0.05). It was also higher in KS than in controls and in nIHH (p<0.05 for both).  210 
 211 212 
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DISCUSSION 213 
 214 
KS is a developmental disorder that associates congenital hypogonadism and anosmia because of 215 
the common ontogenesis of GnRH neurons within olfactory placode. Olfactory impairment, though 216 
variable, is a well-recognized disability in KS patients (2). In contrast, gustative function has been 217 
poorly evaluated in KS. Functional evaluations exploring basic taste were not abnormal in a small 218 
series of KS patients (3). In the same work, an integer sense of flavor was reported in KS, which 219 
prompted the Authors to hypothesize that congenital anosmics might learn by accentuating other 220 
aspects of foods to compensate for their dysfunction (3). 221 
 222 
Flavor is a complex sense deriving from the combination between odorant and gustatory inputs, 223 
and is variously influenced by aspect, texture and temperature (9, 10). In our series KS patients 224 
have reported an intact perception of flavor by self-assessment, in contrast with individuals with 225 
AA, who also complain difficulties in oral intakes identification. 226 
Analysis of olfactory and gustative functions through standard chemosensory tests revealed similar 227 
anosmic scores for KS and AA by sniffin’ sticks, and normogeusic scores for all groups by taste 228 
test. This indicates that the degree of olfactory impairment is similar in the anosmic populations, 229 
and thus differences in FS might not be due to subtle weakening of smell ability. 230 
 231 
It is important to consider that no test is available in routinely clinics to assess flavor. We 232 
developed a test to assess this function based on the identification of oral liquid intakes. This test 233 
explores the capacity of identifying different aromatics dissolved in aqueous solutions, thus 234 
allowing standardization and eliminating putative confounding factors, like consistency, 235 
temperature and appearance (color and shape). Flavor test has shown high reproducibility in both 236 
normal individuals and anosmic populations [see Supplemental Fig. 1].  237 
We clearly show a dramatic injury of flavor perception in KS, that is totally similar to that observed 238 
in AA subjects. Flavor impairment seems not be due to peculiar dietary habits, as all populations 239 
tested resumed similar scores and food choices, consistent with medium adherence to 240 
Mediterranean Diet regimens. A more detailed evaluation of flavor test shows that the distribution 241 
of correct answers is not widely scattered, but some compounds are more frequently perceived 242 
than others. In particular, KS and AA are more able to identify compounds with trigeminal action 243 
than those actually known as pure odorants. Despite this, aromatics with a trigeminal component 244 
are less repeatedly perceived in KS and AA than in normosmics, in line with evidences reporting 245 
an overall fainting of trigeminal stimulation in anosmics (11, 12). 246 
AA patients were older and with higher BMI than KS, nIHH and controls. FS, however, does not 247 
correlate with age or BMI. On the contrary, gender represents a stronger determinant for FS, in the 248 
same way as known for olfactometry, in which better performances are registered in young women 249 
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(13). Flavor Score completely correlates with olfactometric scores, thus representing an optimal 250 
tool to detect clear-cut anosmic from normosmic individuals. Correlation is abolished when 251 
considered anosmic or normosmic populations separately. Although TDI score is not particularly 252 
designed to detect better or worse sniffers among normosmics or anosmics, Flavor Score might 253 
produce different information from simple olfactory volatile impressions that probably could derive 254 
from various combinatory inputs by oral intakes. This deserves to be more appropriately evaluated, 255 
also in specific subpopulations, i.e. involved in perfume, cooking or enogastronomic activities. A 256 
mild hypogeusia has been found in only few subjects, and was not related to a particular 257 
subpopulation. Furthermore, taste scores in these individuals settled just below the lower limits of 258 
normality, reflecting a mild impairment likely not affecting results. Taste scores did not correlate 259 
with flavor scores. We did not use «umami» sense among tastants because barely recognizable or 260 
distinguishable from «salty». 261 
Sex steroid deficiency per se seems not to have a role in flavor perception. Flavor score is strictly 262 
normal in patients with nIHH, who share the same steroidogenic defect as KS. Similarly, hormonal 263 
treatment does not have a role in determining FS. In the overall CHH population, three patients 264 
were not or were insufficiently supplemented with hormonal treatments, and resumed similar 265 
scores. Treatment by HRT or gonadotropins also did not affect FS results. No difference in FS was 266 
registered on the basis of the different mutations in either KS or nIHH genes tested. 267 
 268 
In agreement with what observed in routinely clinics and in previous reports, we confirm that KS 269 
patients are scantly aware of flavor disabilities. Patients were asked specifically about their ability 270 
to perceive flavors, aromatics and to recognize foods and oral intakes in their routinely life. In our 271 
experience, only few KS subjects reported a clear conscience of this inadequacy, whereas the vast 272 
majority was not alerted about this. In line with this finding, the detriment of quality of life related to 273 
the sensorineural inabilities in KS is less critical than in AA, probably reflecting the congenital 274 
nature of the disorder in the former. 275 
It is of interest that, in anosmic population, FS negatively correlated with the QOD – Quality of Life 276 
statements, whereas TDI did not. This may reflect a major importance of flavor dysfunction in 277 
determining quality of life detriment. The importance to use validated questionnaires in this setting 278 
is underlined by the difficulties of a reproducible olfactory ability self-evaluation by simply asking 279 
the patient about the presence or the degree of hyposmia on a visual analogic scale (6, 14). The 280 
scores deriving from the Questionnaire for Olfactory Disorders, particularly designed for anosmic 281 
populations, revealed higher impairment in AA than in KS. 282 
AA patients, who resumed the highest QOD – Quality of Life scores, also scored the lowest QOD – 283 
Sincerity Statements (data not shown), indicating a tendency to give socially desired answers 284 
particularly in this population. This may be due to the older age of AA, since it is known that age 285 
may affect QOD results (6). Alternatively, higher QOD scores in AA may more properly reflect a 286 
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global detriment in general wellbeing, which is more strongly perceived in the acquired form of this 287 
dysfunction. Although other quality-of-life questionnaires have not been specifically tested in this 288 
study, QOD items were designed to explore the complain about daily life problems of disosmic 289 
patients, and have been shown to well correlate with established tests for quality of life and mood 290 
states, as the Beck’s Depression Inventory or the Mood Inventory tests (6). 291 
 292 
Apart from overt anosmics, it will be interesting to evaluate flavor in hyposmic patients, who may 293 
partially have different kinds of odorous impressions. The main question is to explore whether, 294 
through this complete qualitative test, these patients may achieve a full recognition of food, 295 
whereas intermediate scores are resumed at olfactometry. Apart from the scope of this study, it will 296 
be also intriguing to assess flavor function and food identification tasks in patients suffering from 297 
dys- or ageusia, whose main complain seems to solely affect the basic taste ability. 298 
 299 
Flavor disability is both a social and a medical concern. This function is closely associated with the 300 
pleasantness and the sociability of mealtimes, and invariably influences relationships and social 301 
behaviors (4, 15-17). From a medical point of view, recognition of nutrients may prevent ingestion 302 
of spoilt or contaminated foods. Thus, flavor alteration is not merely an inconvenience but can also 303 
impact physical and mental health. Abnormal taste perception in KS might have serious health 304 
consequences by elevating the risk of food-borne illness and by altering food choices with potential 305 
repercussions on nutritional status. Moreover, flavor and taste dysfunction may lead to an 306 
increased risk of allergic reactions in people with food sensitivities and have an impact even on 307 
survival (18). 308 
 309 
In conclusion, this is the first report showing that, along with smell impairment, KS patients also fail 310 
to identify oral intakes. Flavor deficiency has to be accounted as a specific sensorineural 311 
impairment in KS, whose spectrum of associated disabilities is expanding. KS patients should be 312 
apprised of their gustative inability in order to prevent nutritional imbalance and life-threatening 313 
accidents.  314 
 315 316 
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Legend to Figures 394 
 395 
Figure 1 – Sensorineural perception and evaluation in healthy controls, KS, nIHH and AA 396 
patients. 397 
Data are reported as individual values in all panels. Details for each sensorineural test are given in 398 
Methods’ Section. KS: Kallmann Syndrome; nIHH: normosmic isolated hypogonadotropic 399 
hypogonadism; AA: acquired anosmia. ** p<0.01; *** p<0.001. 400 
Panel A. Olfactory perception by self-assessment (0-10 color-intuitive arbitrary scale). Higher 401 
values denote better perception. 402 
Panel B. Gustative perception by self-assessment (0-10 color-intuitive arbitrary scale). Patients 403 
and controls were instructed to indicate their subjective ability to perceive basic tastes (sweet, 404 
salty, sour or bitter). 405 
Panel C. Flavor perception by self-assessment (0-10 color-intuitive arbitrary scale). Patients and 406 
controls were particularly instructed to indicate their subjective ability to perceive flavors and 407 
identification of different foods by ingestion. 408 
Panel D. Olfactory function evaluated by Sniffin’ Sticks® test (SS-Burghart Medical Technology, 409 
Wedel, Germany, see Methods). On the y-axis is reported the relative TDI Score (range 0-48).  410 
Panel E. Gustatory sensitivity evaluated by gustometry (see Methods). On the y-axis is reported 411 
Taste Score (range 0-16).  412 
Panel F. Flavor function evaluated by flavor test (see Methods). On the y-axis is reported Flavor 413 
Score (range 0-21). 414 
 415 
Figure 2 – Linear regression analysis between olfactometry (TDI) and Flavor Score.  416 
Panel A. Correlation between flavor score and olfactometry by TDI score in the overall population. 417 
Individual plots depict the different populations tested. On the x-axis olfactometry by TDI scores; 418 
on the y-axis the flavor scores. The overall population is represented. R=0.89, p<0.0001. Slope is 419 
0.45±0.03, 95% CI [0.39; 0.49]. 420 
Panel B. Correlation between flavor score and TDI score in the anosmic population (KS + AA). 421 
R=0.16, p 0.27. 422 
Panel C. Correlation between flavor score and TDI score in the normosmic population (controls + 423 
nIHH). R=0.12, p 0.36. 424 
KS: Kallmann Syndrome; nIHH: normosmic isolated hypogonadotropic hypogonadism; AA: 425 
acquired anosmia. 426 
 427 
Figure 3 – Flavor perception according to aromatic characteristics.  428 
Histograms represent the rate of correct answers given for compounds with trigeminal or pure 429 
odorant properties (see also Ref. 19 and 20). Compounds with putative trigeminal or putative 430 
 16 
mixed stimulation were not considered. Aromatics with trigeminal properties (black bars) here 431 
reported are peppermint, mustard and garlic. Aromatics with pure odorant properties (white bars) 432 
are vanilla, almond, chocolate, tea, honey, banana, coffee, peach and chestnut. Statistical 433 
significance by Fishers’ exact test is given. A strong difference was also found between controls 434 
and nIHH versus KS (p<0.0001 for both), and AA (p<0.0001 for both, data not shown). 435 
KS: Kallmann Syndrome. AA: acquired anosmia. nIHH: normosmic isolated hypogonadotropic 436 
hypogonadism. * p<0.05; ** p<0.01; **** p<0.0001. 437 438 
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Table 1. Characteristics of sample population. 439 
 440 
 Controls KS nIHH AA 
N. 58 30 12 24 
Sex ratio, males (%) 41 (71) 24 (80) 10 (67) 16 (73) 
Age (range, ys) 32 ± 10  
(21-63) 
29 ± 9  
(18-54) 
23.2 ± 5.5 
(18-31) 
54 ± 13  
(20-70) a 
BMI (kg/m2) 23 ± 3 24 ± 4 23.7 ± 3.1 29 ± 6 b 
Mutations, N. 
KAL1 
FGFR1/FGF8 
PROK2/PROKR2 
GNRH1/GNRHR 
  
9 
5 
2 
 
 
 
1 
2 
 
PREDIMED Score 8 ± 2 6.8 ± 1.6 8 ± 1.6 8.4 ± 1.7 
QOD-Quality of Life Score 4.2 ± 1.6 13.1 ± 6.5 c 3.8 ± 1.7 33.6 ± 4.3 d,e 
 441 
Data are reported as mean ± standard deviation, or as number (percentage). KS: patients 442 
with Kallmann Syndrome; nIHH: patients with normosmic isolated hypogonadotropic 443 
hypogonadism; AA: patients with acquired anosmia. PREDIMED: 14-Item Mediterranean Diet 444 
assessment (see Methods); QOD: Questionnaire for Olfactory Disorders (see Methods). 445 
a: p<0.001 vs Controls, KS and nIHH; b: p<0.05 vs Controls and KS; c: p<0.05 vs Controls 446 
and nIHH; d: p<0.0001 vs Controls and nIHH; e: p<0.05 vs KS. 447   448 
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